CA1074313A - Process for the production of new triazole derivatives - Google Patents

Process for the production of new triazole derivatives

Info

Publication number
CA1074313A
CA1074313A CA229,230A CA229230A CA1074313A CA 1074313 A CA1074313 A CA 1074313A CA 229230 A CA229230 A CA 229230A CA 1074313 A CA1074313 A CA 1074313A
Authority
CA
Canada
Prior art keywords
general formula
triazole
methyl
chlorophenyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA229,230A
Other languages
French (fr)
Inventor
Rene Meier
Roland Heckendorn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of CA1074313A publication Critical patent/CA1074313A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ABSTRACT OF THE DISCLOSURE

The invention relates to processes for the production of new triazole derivatives of the general formula (1) wherein R1 represents hydrogen, lower alkyl, hydroxymethyl, lower alkanoyloxy methyl, lower alkoxy methyl, formyl, car-boxy, lower alkoxy carbonyl, cyano or a group of the partial formula I aa (I aa) in which X represents oxygen or two hydrogen atoms and R4 and R5 each independently represent hydrogen, lower alkyl having at most 3 carbon atoms, or together with the adjacent nitrogen atom, they represent mor-pholino, 1-pyrrolidinyl, or piperidino, R2 represents lower alkyl, R3 represents hydrogen or lower alkyl or together with the adjacent nitrogen atom they represent morpholino, 1-pyrrolidinyl or piperidino the rings A and B independently of each other are unsub-stituted or substituted by halogen up to atomic number 35, trif1uoromethyl, nitro, lower alkyl or lower alkoxy and their addition salts.
These new substances possess valuable pharmacological properties. In particular they have an anticonvulsive activity and are useful as active substances for therapeutic prepara-tions for the treatment of epilepsy and of conditions of tension and of agitation.

Description

1~743~3 The present invention relates to processes for the production of new triazole derivatives and their acid addition salts, to these new substances themselves and to pharmaceutical compositions containing thcm, as well as to the therapeutic application of the new substances.

The new triazole derivatives according to the invention correspond to the general formula I

7~ ~N

~ ~C~ N (I) ~\

where~n Rl represents hydrogen, lower alkyl, hydroxymethyl, lower alkanoyloxy methyl, lower alkoxy methyl, formyl, car-boxy, lower alkoxy carbonyl, cyano or a group of the partial formula I aa ¦1 / 4 - C - N (I aa) \ R
- 2 -1~74;~3 in which X represents oxygen or two hydrogen atoms and R4 and R5 each independently represent hydrogen, lower alkyl having at most 3 carbon atoms, or together with the adjacent nitrogen atom, they represent mor-pholino, l-pyrrolidinyl, or piperidino, R2 represents lower alkyl, R3 represents hydrogen or lower alkyl or together with the ad~acent nitrogen atom they represent morpholino, l-pyrrolidinyl or piperidino the rings A and B independently of each other are unsub-stituted or 8ubstituted by halogen up to atomic number 35, trifluoromethyl, nitro, lower alkyl or lower alkoxy, and the~r addition salts.

In the triazole derivatives of the general formula I, Rl as lower alkyl i8, e.g., ethyl, propyl, butyl, isob~tyl, pentyl, isopentyl, neopentyl (2,2-dimethylpropyl), hexyl or isohexyl and, in particular, methyl; as lower alkanoyloxy-methyl it i8, e.g. formyloxymethyl, propionyloxymethyl, buty-ryloxymethyl, pivaloyloxymethyl and, in particular, acetoxy-methyl; and as lower alkoxymethyl it is, e.g. methoxy-, ethoxy-, propoxy-, isopropoxy-, butoxy-, isobutoxy-, sec.butoxy-, pentyloxy-, isopentyloxy-, neopentyloxy-, hexyloxy- or iso-hexyloxymethyl. As lower alkoxy alkoxycarbonyl Rl is, e.g.
propoxycarbonyl, butoxycarbonyl, isobutyloxycarbonyl, 1~74313 pentyloxycarbonyl, isopentyloxycarbonyl, hexyloxy-carbonyl and, in particular, methoxycarbonyl or ethoxycarbonyl; and, optionally, mono- or disubsti-tuted carbamoyl. Substituents of carbamoyl groups Rl as well as of aminomethyl groups Rl are on the one hand, lower alkyl, e.g. propyl, isopropyl, butyl, isobutyl, sec.butyl, pentyl, isopentyl, neopentyl, hexyl or heptyl, and especially methyl or ethyl.

~' ,. ,j,~

1~743i3 The lower alkyl R2 and the radical R3 as lower alkyl are, for example, propyl, isopropyl, butyl, isobutyl, sec.butyl, pentyl, isopentyl, neopentyl, hexyl or heptyl, and particularly methyl or ethyl.
Where reference is made in the foregoing and in the following to lower groups, then those meant are groups having at most 7 carbon atoms and preferably at most ~ carbon atoms.
The rings A and B can each on its own be re-peatedly substituted: but ring A is preferably monosubsti-tuted and ring ~ preferably unsubstituted or disubstituted and, in particular, monosubstituted. The substituents are, for example, halogen up to atomic number 35, trifluoromethyl, 1~74313 nitro, lower alkyl or lower alkoxy. A substituent of the ring ~ is preferably in the 4-position with respect to the triazole ring, and the substituent(s) of the ring B
in the onP (or in both) ortho-position(s) with respect to the carbonyl group. Halogen atoms as substituents of the rings A and B are fluorine, chlorine or bromine atoms; lower alkyl is, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.butyl, pentyl, isopentyl, neopentyl, tert.pentyl, hexyl or heptyl; and lower alkoxy is, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentyloxy, isopentyloxy, hexyloxy or heptyloxy. A substituent of the ring A, preferably in the 4-position to the triazole ring, is, in particular, one of the mentioned halogen atoms, especially chlorine, also nitro or trifluoromethyl. The ring ~ is preferably unsubstituted, or substituted by fluorine, chlorine, bromine or trifluoromethyl in any position, particularly, however, by fluorine or chlorine in the o-position.

The triazole derivatives of the general formula I
and their addition salts with inorganic and organic acids possess valuable pharmacological properties. They have, in particular, an anticonvulsive action, as can be veri~ied, 1~74313 . .
for example, on the mouse in the pentetrazole convulsion test after administration of oral doses of from about 0.3 mg/kg, as well as in the strychnine convulsion tes~
and in the electroshock test after administration in each S case of oral closes of from about 1 mg/kg, for example of 1-[2-(o-chlorobenzoyl)-4-chlorophenyl]-5-(morpholino-methyl)-lH-1,2,4-triazole-3-carboxamide or N,N-dimethyl-1-[2-(o-fluorobenzoyl)-4-chlorophenyl]-5-[(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxamide. Furthermore, the triazole derivatives of the general formula I and their acid addition salts also have a moderate central depressant action. The mentioned properties, together with others that can be demonstrated by selected standard tests lsee W. Theobald and H.A. Kunz, Arzneimittelforsch. 13, 122 (1963) as well as W. Theobald et al., Arzneimittel-forsch. 17, 561 (1967)1, characterise the triazole derivatives of the general formula I and their pharmaceut-ically acceptable addition salts with inorganic and organic acids as being active substances for anticonvulsants and tranquillisers which are usable for the treatment of epilepsy and of conditions of tension and agitation.
Various triazole derivatives of the general formula I

are moreover suitable as intermediates for the production .: .
. ' ':

.

-1~74313 of further compounds embraced by this general formula.
The invention relates, in particular, to triazole derivatives of the general formula I in which Rl, R2 and R3 have the meanings given under this formula, ring A
is 6ubstituted in the ~-position with respect to the triazole ring by halogen up to atomic number 35, especially . ~

1~743~3 by chlorine, or by nitro or trifluoromethyl, and ring B
i8 unsubstituted, or substituted in any position by halogen up to atomic number 35 or by trifluoromethyl, preferably however by fluorine or chlorine in the ortho-position .
Triazole derivatives of the general formula I wherein :. ~

. :

10743~.3 Rl represents hydroxymethyl, formyl, carboxy or lower alkoxycarbonyl, while R2 and R3 have the meanings given under formula I or preferably the more restricted meanings given in the foregoing, and the rings A and B
can be substituted as given under formula I, preferably however in the manner previously specified, are especially important as intermediates for the production o~ other pharmacologically valuable compounds embraced by the general formula I, as well as of other such compounds.
Compounds of the general formula I having a carboxy group or lower alkoxy carbonyl group as Rl are of particular importance as intermediates on account of the ease with which they can be produced.

The data given in the foregoing relate likewise to the addition salts of the stated triazole derivatives embra~ed by the general ormula I with inorganic and organic acids, especially to the pharmaceutically acceptable acid addition salts.

The new triazole derivatives of the general formula I
B ~h~ drde~ ~c~/~ ~cc~y~7~
~20 and their~acld a ition sa ts are'produced according to the invention by a process wherein a) a reactive ester of a compound of the general ' ~ , ' :, :''~ ' ~743~3 formula II
IR
~C~

N _ ~

CO (II) selected from the group consisting of hydrohalic acid esters and sulfonic acid esters, in which Rl has the meaning given under formula I, and the ring~ A and B are as hereinbefore defined, i8 reacted with a co~pound of the general formula III

~ R (III) whereln R2 and ~3 have the meanings given under formula I, or with an aIkali metal derivative of such a compound in which R3 has a meaning other than hydrogen; or b), for the production of compounds of the general formula I

wherein R2 and R3 represent methyl, ~hile Rl has the meaning given under formula I, a compound of the general formula IV

' ~ :

io743i3 ~,C ~
I, Ic ~ C N / (IV) in which Rl has the meaning given under formula I~ and the rings A and B are as hereinbefore defined is reacted with for~aldehyde and formic acid, or c), for the production of compounds of the general formula I wherein Rl has the meaning given under formula I with the exception of hydroxymethyl, while R2 and R3 have the meanings given under formula I, a compound of the general formula V

~,C ~

C 2 \ (V) CH-OH
,~

1~743~3 in which Rl, R2 and R3 have the meanings given under formula I, and the rings A and B are as hereinbefore defined is oxidised; or d), for the production of compounds of the general formula I wherein Rl represents carboxy or lower alkoxy-carbonyl, while R2 and R3 have the meanings eiven under formula I, a basic medium is allowed to react with a co~pound of the general formula VI

fO-O-R6 C~O-O-R6 N NH
Il I
2-N ~ 2 (~I) CO

in which R6 represents lower alkyl, R2 and R3 have the meanlng~ given under formula I, and the rings A and B can be substituted as defined there;
and, optionally, a compound I obtained by any one of the , , ' ' ' ~ ', :

1~374313 n~ ~ p~ay~n~C~t, c ~ p~L/~
V ~ processes given under a) to d) is converted into~r addition salt with an inorganic or organic acid.

In tria~ole derivatives embraced by the general formula I, it is possibl.e, within the limits of the definition for these compounds, to introduce, split off or modify substituents in the usual manner, i.e. to convert triazole derivatives of the general formula I
in the usual manner into other final materials o the general formula I as defined. Thus, compounds of the general formula I are obtained by a process wherein e), for the production of compounds of the general formula I wherein Rl represents optionally mono- or disubstituted carbamoyl, while R2 and R3 have the meanings given under formula I, a carboxylic acid of the general formuLa I e embraced by the general formula I
0 0~1 ~C~
N

Cll ~ 2 ( I e) 1~74~13 in which R2 and R3 have the meanings given under formula I, and the rings A and B are as hereinbefore defined, or a reactive functional derivative of such a carboxylic acid, is reacted with a compound of the general for-mula VII

H - N (VII) in which R4 and R5 each independently represent hydrogen or hydrocarbon radicals each having at most 10 carbon atom6, which, provided that they represent lower alkyl, can also be bound directly together, or they can be bound in the ~- or y-po6ition by way of oxygen, sulphur, the imino radical or a lower alkylimino radical, or with a reactive functional derivative of such a compound; or f), for the production of compounds of the general for-mula I wherein Rl is aminomethyl or mono- or disubsti-tuted aminomethyl, while R2 and R3 have the meanin8s given under the general formula I, a reactive ester of a compound of the general formula I f embraced by the gener~1 formula I

~o743~3 fH2-OH
~C ~

2 N - R (I f) ~3 in wh~ch R2 and R3 have the meanings given under formula I, and the rings A and B are as hereinbefore defined, is reacted with a compound of the general formula VII
given above, wherein R4 and R5 have the meanings given under this formula, or with an alkali metal derivative of such a compound; or g), for the production of a triazole derivative of the general formula I wherein Rl represents hydroxymethyl, whlle R2 and R3 have the meanings given under formwla I, a co~pound of the general formula VIII

~74313 CH2-0-Ac ~C \

2 N \ (VIII) CO

in which Ac represents the acyl radical of an organic acid, R2 and R3 have the meanings eiven under formula I, and the rings A and B are as hereinbefore defined, is solvolysed; or h), for the production of a triazole derivative of the general formula I wherein Rl represents formyl, while R2 and R3 have the meanings given under formula I, a compound of the gener~l formula I h Cl H2-()H
~`
D
~ CH2 N \ tI h) ~1~74313 in which R2 and R3 have the meanings given under formula I, and the rings A and B are as hereinbefore defined, is oxidised, or i), for the production of a triazole derivative of the general formula I wherein Rl represents cyanc, while R2 and R3 have the meanings given under formula I, a compound of the general formula I i ~C\
N N

\ CH2-N / (I

CO

in wh~ch R2 and R3 have the meaning~ given under formula I, and the rlngs A and B are as hereinbefore defined, is dehydrated, or J), for the production of triaæole derivatives of the general forml~la I wherein Rl represents optionally mono-or disubstituted carb~moyl, while R2 and R3 have the - lô -meanings given under formula I, a compound of the general formula I ; embraced by the general formula I

CHO
I

N~C~

~ CO \ CX2-~ / (I J) in which R2 and R3 have the meanings given under form~la I, and the rings A and B are as hereinbefore defined, is reacted with a compound of the general formula VII
previously given, wherein R4 and R5 have the meanings given under formula VII, in the presence of ~n alkali metal cyanide and of a ~elective oxidising agent, ~nd, optionally, a triazole derivative of the general formula I
obtained by any one process or by several successive proces~e~ according to e) to J) is converted into a pharma-ceutically acceptable addition salt with an inorganic or organic acid.
For process a), suitable reactive ester~ of hy-droxy compounds of the genersl formula II are, for example 1~74313 hydrohalic acid esters such as chlorides and bromides, as well as the iodides produced from these, optionally in situ not until immediately before the subsequent reaction. Further suitable reactive esters of compounds of the general formula II are sulphonic acid esters thereof, particularly lower alkanesulphonic acid esters such as the methanesulphonic acid esters, and arenesulphonic acid esters, such as the o- and p-toluenesulphonic acid esters, the o- or p-nitrobenzenesulphonic acid esters or the o- or p-chlorobenzenesulphonic acid esters. The reactions with compounds of the general formula III are preferably performed in the presence of an acid-binding agent. As the acid-binding agent, it is possible to use an excess of the compound of the general formula III, or, e.g , also a tertiary organic base such as ethyl-dii.sopropylamine or collidine, or an inorganic basic substance such as potassium carbonate. The reaction medium employed can be , e.g., an in~rt, optionally hydrous, solvent, e.g. a lower alkanol such as methanol, ethanol, propanol, isopropanol or butanol, a ketone such as acetone or methyl ethyl k~tone, also, e.g., dioxane, tetrahydro-furan, dimethylformamide or dim~thylsulphoxide, or an excess of the compound of the general formula III, as such or as an a~ueous or organic solution.

' .

1~74313 If there is used as reactant, instead of the compound of the general formula III, an alkali metal derivative of such a compound, e.g. a sodium, lithium or potassi-lm derivative, then as solvent there are preferably used hydrocarbons such as benzene, toluene or xylene, ethereal liquids such as 1,2-dimethoxyethane, tetrahydrofuran or dioxane, acid amides such as dimethyl-formamide or N,N,N',N',N",N"-hexamethyl-phosphoric acid triamide, or sulphoxides such as dimethylsulphoxide. The alkali metal derivatives of such compounds of the general formula IlI in which R3 has a meaning other than hydrogen are formed preferably in situ, e.g. by the addition of an at least equimolar amount of alkali metal hydride such as sodium hydride, alkali metal amide such as sodium amide or lithium amide, or of an alkali-metalloorganic compound such as phenyl- or butyllithium. The reaction temperature is preferably between 0 and 120C, or it is the boiling temperature of the reaction medium employed.

Some chlorides of compounds of the general formula II
are described, as intermedia~es, in the German 'Offenlegungs-schriften'Nos. 2,159,527, 2,215,943 and 2,304,307. Other reactive esters of compounds of the general formula II
can be produced analogously.

1~74313 In the splitting of the diazepine ring according to Process b) by means of formaldehyde and formic acid, the result is not only that the amino group previously belonging to the diazepine ring is dimethylated, but also that an optionally present aminomethyl and monosubstituted aminomethyl Rl is di- and monomethylated, respectively The splitting according to the process is performed at elevated temperature, preferably at about 80~C up to the boiling temperature of the reaction mixture. Although not absolutely necessary with respect to the overall balance of the reaction, an appreciable content of water in the reaction mixture is advantageous; it is therefore possible to use either a~ueous, e.g., 30 to 36%
~ormaldehyde solution or aqueous, e.g., 85 to 95% formic acid. The ~ormaldehyde is preferably used in a considerable cxeess, e.g. two to ~ive times the theoretical amount of 2 to 4 moles per mole of starting material of the general formula IV, and the formic acid in an even greater excess, e.g. two to five times the molar amount relative to the formaldehyde. Of the starting materials of the general formula IV, those with hydrogen, carbo~y or lower alkoxycarbonyl as Rl are described in the Germ~n 'Offenlegungsschriften' Nos. 2,159,527 and 2,215~943, those with lower alkyl or hydrogen as Rl in the German . . .

: .,; -. . -lV74313 'Offenlegungsschriften' Nos. 2,055,889 and 2,159,527, those with optionally mono- or disubstituted aminomethyl or with hydroxymethyl as Rl in the German 'Offenlegungs-~chrift' No. 2,234,652, and those with optiona]ly mono-S or disubstituted carbamoyl or with formyl as Rl in the German 'Offenlegungsschrift' No. 2,304,307. Further compounds of the general formula IV can be produced by methods analo~ous to those described in the aforementioned 'Offenlegungsschriften'.

The oxidation according to Process c) is performed, for example, by means of a higher metal oxide such as chromium trioxide, e.g. ~issolved in acetic acid, or dissolved in dilute sul~huric acid as oxidation solution according to Jones and gradually added to the solution lS o~ the starting material in acetone, at a temperature o~ between about 0 and 60C, preferably at 2~-30~C;
or with manganese dioxide, particularly in the activated form d~scribed by J Attenburrow et al., J.Chem. Soc.
1952, 1104, in an inert organic solvent, such as ben~ene or dioxane, at temperatures of between room temperature and the boiling temperature o the reaction medium Starting materials of the general formula V are obtained, 1~37431~

for example, by reduction of reactive esters of compounds of the general formula II, especially chlorides, with an alka]i metal borohydride, such as sodium borohydride, in a lower alkanol such as methanol, or in some other S suitable organic solvent such as tetrahydrofuran, at low temperatures, preferably between about -20C and 0C, and reaction of the resulting reduction products with compounds of the general formula III in a manner analogous to that in Process a).

Furthermore, starting materials of the general formula V can be obtained, e.g., also by reduction of compounds of the general formula I, whereby a suitable reduction process or catalytic hydrogenation, e.g. in the presence of Kaney nickel or of a noble metal catalyst, such as palladiurn on charcoal or on an alkaline-earth metal carbona~e, can be selected in the case where groups Rl tha~ are in themselves reducible are to be retained intact.
The oxidation according to c), together with the preceding reduction, is however more advantageously applied to such compounds of the general ~ormula I which contain a group ~1 the reduction of which is desired but not possible, or only possible with difficulty, without the simultaneous reduction o~ the carbonyl group situated between the ~ngs A and B. For example, a compound of the general 1~74313 formula I in which Rl is disubstituted carbamoyl can be reduced by means of a complex hydride, such as lithium aluminium hydride, in an ethereal solvent, such as tetrahydrofuran, to a compound of the general formula V
in which Rl is the corresponding disubstituted aminomethyl.
In addition, it is possible in an analogous manner to reduce a compound of the general formula I wherein R
is lower alkoxycarbonyl to a compound of the general formula V wherein Rl is hydroxymethyl. If the reduction product is thereupon directly oxidised, then the hydroxy-methyl group Rl is attacked before the hydroxymet ffllene group, and there is firstly formed, depending on the oxidising agent used, a formyl group or carboxyl group Rl, and immediately afterwards there occurs in the same operation the oxidation of the hydroxymethylene group to the carbonyl group. Since compounds of the general formula I
having a carboxy group Rl are more easily obtainable in another m~nner, particularly the oxidation of a hydroxymethyl group Rl to ~ formyl group R1 (in an analogous manner to that of ZO Yroces~ (h~, e.g. by means of the above-mentioned oxidation solution according to Jones), in the same operation as the ox-idation of the hydroxymethylene group according to Process c) ls of practical importance. Alternatively, it is possible in 1~743~3 an above-mentioned reduction product to also firstly selectively acylate, e.g. acetylate, the hydroxymethyl group Rl, to then carry out oxidation according to c) and, optionally, to subsequently again liberate the hydroxymethyl group according to Process g).

Cyclisation of compounds of the general formula VI
according to d) is performed, e.g., in a diluted aqueous or aqueous-organic alkali hydroxide solution, especially sodium hydroxide or po~assium hydroxide solution, as a basic medium, at room temperature or at moderately elevated temperatures up to the boiling temperature of the reaction medium. The organic solvent used is, e.g., dioxane or a lower alkanol such as ethanol. If mild reaction conditions are chosen, e.g. if the at most double-molar amount, relative to the compound of the general ormula VI, of alkali hydroxide is allowed to react at room temperature, and the reaction mixture is n~utralised before processi~g, then as the main product there is obtained a triazole derivative of the general formula I in which Rl is the lower alkoxy carbonyl corresponding to the group R6; whilst under less mild conditions the corresponding carboxylic acid, i.e. the com~ou~d of the general formula I having carboxy as Rl, is obtained.

: . -'' i~74313 Cyclisation can also be performed by means of an aqueous-organic ammonia solution as basic medium, e.g. in 2 mixture of concentrated aqueous ammonia and dimethyl-formamide.

Starting materials of the general formula VI are obtained, for example, by reaction of the analogous compounds described, as intermediates, e.g., in the German 'Offenlegungsschriften' Nos. 2,159,527, 2,215,943 and 2,304,307, which compounds contain a halogen atom, especially a chlorine atom, instead of the disubstituted amino group, with a compound of the previously given general formula III in which R2 and R3 have the meanings defined there, or with an alkali metal derivative thereof, analogously to Process a) for the production of the lS tria~ole derivatives of the general ~ormula I. The simul~ancous occurrence of an aminolysis o~ the carboxylic acid ester groups is avoided if necessary in the case of reactions with primary or secondary amines of the general formula III having lower radicals R2 and R3 by employing mild reaction conditions and/or only a slight excess of such amines, or by use of secondary amines in the form of their alkali metal derivatives.

Process e) is performed by reacting, for example, a iO~4313 carboxylic acid of the general formula I e with a compound of the general formula VII in the presence of a carbodiimide, such as dicyclohexyl-carbodiimide, in an inert solvent such as tetrahydrofuran. Furthermore, a carboxylic acid of the general formula I e can be allowed to react with a lower alkylisocyanate or alkyl-thiocyanate - as reactive functional derivative of a compound of the general formula VII - and the immediate reaction product heated until evolution of carbo~ dioxide or carbon oxysulphide ceases Suitable reactive functional derivatives of carboxylic acids of the general formula I e are, for example, lower alkyl esters thereof, which can be reacted with compounds of the general formula VII in some cases even at room temperature or, where necessary, wlth heating and, if required, in a closed vessel, depending on the reactivity and boiling temperature of the employed compound of the general formula VII As the reaction medium in this case it is possible to use, e.g., a lower alkanol such as methanol or ethanol, or another inert organic solvent such as tetrahydrofuran or dioxane, optionally together with an excess of the compound to be reacted of the general formula VII.

,. .. .

Further suitable reactive functional derivatives of carboxylic acids of the general formula I e are halides thereof, especially chlorides, particularly in the form of their hydrohalides, such as hydrochlorides.
S These are produced preferably directly before the subsequent reaction with the compounds of the general formula VII
from the corresponding free carboxylic acids and suitable acid halides such as thionyl chloride, oxalyl chloride or phosphorus tribromide, and further reacted without purification The carboxylic acid halides or their hydrohalides are reacted with compounds of the general formula VII, preferably in the presence of the at least equivalent or at least double-equivalent amount of an acid-binding agent, e.g. of a strong tertiary organic base such as triethylamine, N-ethyl-~iisopropylamine, pyridine or s-collidine, which in excess can also serve as reaction medium, or in the presence of a corresponding excess of the compound of the general formula VII to be reacted, in the presence or absence of an inert organic solvent, such as dioxane, tetrahydrofuran, benzene or dimethyl-formamide, at a temperature of between about 0C and 100C, or at the boiling temperature of the reaction medium in the case where this is lower. It is possible 1~74313 under analogous reaction conditions to react also mixed anhydrides of carboxylic acids of the general formula I e, especially the mixed anhydrides with carbonic acid semi-esters obtainable, e.g., by reaction of alkali metal salts of such carboxylic acids with chloroormic acid esters, preferably chloroformic acid lower alkyl esters, with compounds of the general formula VII.

Further suitable reactive functional derivatives of carboxylic acid esters of the general formula I e 10 are, e,g., reactive esters such as p-nitrophenyl esters and cyanomethyl esters, which can be reacted with compounds of the general formula VTI in inert organic solvents, if necessary with heating. There are reacted under the same conditions ~he l-imidazolides of carboxylic acids of the general formula I e with compounds of the general formula VII.

As reactive functional derivatives of compounds of the general formula VII, there have already been mentioned lower alkylisocyanates and lower alkylisothiocyanates which are derived from compounds of the general formula VII havlng a hydrogen a~om as R5. The reactions of these with carboxylic acids of the general ormula I e can be performed in the presence or absence of an inert organic
- 3~ -: :
.~
: :

1~74313 solvent having a sufficiently high boiling point or boiling range, e.g. toluene or xylene or an xylene mixture. Further reactive functional derivatives of compounds of the general formula VII having a hydrogen atom as R5 are, e.g., the N-tri-(lower alkyl)-silyl derivatives obtainable by reaction of these compounds with tri-(lower alkyl)-silyl chlorides, such as trimethylsilyl chloride, in inert anhydrous organic solvents, The reaction thereof with reactive functional derivatives o carboxylic acids of the general formula I e in inert organic solvents yields N-tri-(lower alkyl)-silyl derivatives of carboxamides embraced by the general formula I, from which the desired carboxamides are liberated by decomposition with water or with lower alkanols, ~ uitable unctional derivatives of such compounds o the general formula VII in which neither R4 nor R5 represents hydrogen are, e.g " N-chlorocarbonyl deri~atives thereof. These are reacted with salts, e,g, alkali metal salts of carboxylic acids of the general formula I e in the presence or absence o~ inert organic solvents, such as toluene or dimethylformarnide, and the reaction mixtures are heated until the equimolar amount of carbon 1~74313 dioxide is liberated from the primarily formed carboxylic acid-carbamic acid-anhydrides Likewise from compounds of the general formula VII wherein neither of the radicals R4 and R5 represents hydrogen are derived, e.g., sulphurous acid-monoalkyl ester-monoamides, which yield, on reaction with carboxylic acids o the general formula I e in organic solvents, e.g. in pyridine, dioxane or dimethylormamide or in benzene, the desired carboxamides embraced by the general formula I.

Suitable reactive esters of compounds of the general formula I f are, for example, sulphonic acid esters thereof, particularly Lower alkanesulphonic acid esters such as methanesulphonic acid esters, and arenesulphonic acid e~ters such as o- and p-toluenesulphonic acid ester6, o- or p-ni~robenzenesulphonic acid estcrs or o- or p-chloroben~enesulphonic acid esters. Further suitable reactive esters of compounds of the general formula I f are hydrohalic acid esters thereof, especially chlorides and ~romides, as well as the iodides produced in situ t~erefrom The reactions with compounds o the general formula VII or with their alkali metal derivatives can be performed analogously to Process a~.

The compounds of the general formula I f can be produced by various processes according to the invention, e.g. by Process b) if R2 and R3 are to be methyl, and particularly by Process g), and converted by methods known per se into reactive esters. A further production possibility for the organic sulphonic acid esters embraced also be the general formula VIII of the starting materials for Process g) is given later on in the text.

In the starting materials of the general formula VIII
for Process g), the acyl radical Ac is preferably the acyl radical of a carboxylic acid, of a carbonic acid semi-ester or of an organic sulphonic acid. As an acyl radical o~ a carboxylic acid, Ac is, e.g., lower alkanoyl such as formyl, propionyl, butyryl, isobutyryl, valeryl lS or pivaloyl and, in particular, acetyl, also, e.g., halogenated lower alkanoyl such as trifluoroacctyl or ~ri~hloroace~yl, or arenecarbonyl such as benzoyl, p-chlorobenzoyl or p-nitrobenzoyl. As an acyl radical of a carbonic acid semi-ester, Ac is, e.g., methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, tert.-butoxycarbonyl, phenoxycarbonyl or benzyloxycarbonyl, and as an acyl radical of an organic sulphonic acid, it is, e.g., lower alkylsulphonyl such as methylsulpl~onyl, or i874313 arylsulphonyl such as phenylsulphonyl, o- or p-tolyl-sulphonyl, o- or p-nitrophenylsulphonyl or o- or p-chlorophenylsulphonyl. The solvolysis of compounds of the general formula VIII according to g) can be S performed by methods known per se in a basic or acid medium, for example in lower-alkanolic or lower-alkanolic-aqueous alkali hydroxide solutions, at room temperature up to the boiling temperature of the reaction mixture, or with aqueous OL' aqueous-organic mineral acids, e.g.
in dilute hydrochloric acid, to which is optionally added a water-miscible organic solvent such as dioxane, tetrahydrofuran, methanol or ethanol, at the same temperatures.
The starting materials of the general formula VIII
are obtained, for example, starting from compounds of the general formula I wherein Rl is lower alkoxycarbonyl by simultaneous reduction of this group to the hydroxy-methyl group and of the carbonyl group situated between the rings A and B to the hydroxymethylene group by means of a complex hydride, such as lithium aluminiuAm hydride, i.n an ethereal solvent, such as tetrahydrofuran, at a temperature of bet~een about 0~ C and room temperature, followed by partial acylation of the hydroxymethyl group 1r374313 by methods known per se; and finally oxidation of the hydroxymethylene group to the carbonyl group, analogously to the aforementioned Process c) for the production of compounds of the general formula I.

For the oxidation of triazole derivatives of the general formula I h to triazole derivatives of the general formula I having formyl as Rl according to Process h), there are used mild selective oxidising agents, such as dimethylsulphoxide, optionally in the presence of a water-binding agent, such as dicyclohexyl-carbodiimide and phosphoric acid, at room temperature or at modera~ely elevated temperatures up to about 100C;
or manganese dioxide, which is preferably activated according to J. Attenburrow et al., J.Chem.Soc. 1952, l~ 1104, in an inert organic solvent at a temperature of between about 50C and the boiling temperature of th2 solvent, e.g. in boiling benzene, The oxidising agent employed can also be chromium trioxide, e.g. dissolved in dilute sulphuric acid as an oxidation solution according to Jones, with this oxidation solution being slowly added, preferably at between 0C and room temperature, to ~he solution of ~he starting ma~erial in acelone The /q l h starting materials of the general ~e~mula I c are produced 1~743~3 for example, by the aformentioned Process g) or, if R2 and R3 are methyl, also by Process b).

Dehydration of the triazole derivatives of the general formula I i according to Process i) can be performed~ by methods known per se, at room temperature or at elevated temperatures up to about 180C. For example, there is allowed to react with a carboxamide of the general formula I i an organic or inorganic acid halide, especially a sulphonic acid halide such as p-~oluenesulphonyl chloride or methanesulphonyl chloride, or a halide of an acid of trivalent or pentava3.ent phosphorus, such as phosphorus oxychloride, or an acid anhydrlde, particularly the anhydride of an inorganic oxygen acid such as phosphorus pentoxide, in an inert organic solvent such dimethylformamide or xylene~ The sulphonic ac.id halid~, such as p-toluenesulphonyl chloride, are uscd preferably in an equimolar amount or in a moderate excess, optionally together with a somewhat gre~ter excess of an acid-binding agent, especially of a tertiary organic base such as pyridine~ Dehydration can ~or example be performed at room temperature, or if necessary at slightly elevated te~peratures, by means of the approx 1.5-fold molar amount of p-toluenesulphonyl chloride and the app~ox.

'''' ', ' ' '' :" ' :

i~74313 2-fold to 3-fold molar amount of pyridine in dimethyl-formamide. A further example of a dehydrating agent to be mentioned is triphenylphosphine, which can be caused to react, e.g., in a halogenated hydrocarbon, such as carbon tetrachloride, with a carboxamide of the general formula I i. The starting materials of the general formula I i can be produced by a number of the aforementioned processes, particularly by Process e).

As alkali metal cyanide for Process j), there are used, for example, potassium cyanide and, in particular, sodium cyanide. By selective oxidising agents are meant those which do not under the reaction conditions attack the aldehycle group of the starting material of formula I j, but which are able to oxidise the hydroxymethylene group of the intermediately formed cyanohydrin to the carbonyl group, A suitable oxidising agent is manganese dioxide, particularly that in the active form described by J.
Attenburrow et al., J Chem Soc 1~52, 1104 The reactions wlth manganese dioxide are preferably performed in isopropanol, or in another lower secondary alkanol, to which can be added a further organic solvent inert under the reaction conditions, preferably one having a good dissolving power for the starting materials of the g~eneral .: .. . .

.. ~

. .
.:

formula I j, such as for example dioxane, in the cold state, e.g. between -10C and +10 C, preferably at about O~C. Relative to the compound of the general formula I j, there is used, for example, a considerable excess of the cornpound of the general formula VII, and also of alkali metal cyanide, e.g. the approx. 5-fold molar amount of the latter and an even greater excess, e.g.
the app-rox. 20-fold molar amount, of manganese dioxide, with a reaction time of 2 to 6, preferably about 4, hours.
The triazole derivatives of the general formula I j, used as starting materials, are produced, for example, by the aforementioned Process h), and also by the Process c) with the use of compounds of the general formula V in which ~1 represents a hydroxymethyl group.

The present invention relates a]so to such modifi~ations o~ ~he proc~sses mentioned under a) to j) and to the preliminary stages thereof, w~lerein a process is interrup~ed at some stage, or wherein a compound occurring as an intermedia~e at some stage is used as starting material and the uncompleted steps are performed, or wherein a starting material is formed under the reaction conditiolls, or, optionally, is used in the ~orm of a salt. If the recluired starting materials are optically active, then ~okh ;, . .. .
. ..

the racemates and the isolated antipodes can be used, or in the case of diasteriomeric compounds either mixtures of racemates or specific racemates, or likewise isolated antipodes can be used. Also such starting materials can, S optionally, be used in the form of salts. The starting materials preferably employed for the carrying out of the reactions according to the invention are those from which are obtained the groups of final materials to which particular reference was made at the commencement of the text.

Depending on the conditions of the process and on A e no/ p~oo~c~c~
the staLting matcLial~, the starting materials are obtained in the free form, or in the form, likewise included in the invention, of their acid addition salts, or in some cases in the form or hydrates of the last-mentioned The acid addition salts of the new compounds of the general formula I can be converted in a kno~m manner in~o ~he free bases, e.g. with basic agents, such as alkalies or ion exchangers. Alternatively, the compounds of the general formula I obtained by the process according to the invention can, optionally, be converted in the usual manner into their addition salts with inorganic or organic acids For examyle, the acid desired as salt component is .

added to a solution of a compound o~ the general formula 1 1~74313 in an organic solvent. Solvents preferably used for the reaction are those in which the occurring salt is diificultly soluble, so that the salt can be separated by filtration. Such solvents are, for example, ethyl acetate, methanol, ether, acetone, methyl ethyl ketone, acetone/ether, acetone/ethanol, methanol/ether and ethanol/ether.

It is possible to use as pharmaceutic active substances, instead o~ free bases, pharmaceutically acceptable acid addition salts, i.e. salts with acids of which the anions are not toxic in the dosage amounts concerned. Moreover, it is of advantage if the salts to be used as pharmaceutical active substances readily crystallise, and are not, or only slightly, hygroscopic. For salt formation with compounds of the general ~ormula I, it is possible to use, e.g., hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acld, methanesulphonic acid, ethanesulphonic acid, 2-hydroxyethanesulphonic acid, acetic acid, lactic acid, succinic acid, ~umaric acid, maleic acid, malic acid, tartaric acid, citric acid, benzoic acid, salicylic acid, phenylacetic acid, mandelic acid and embonic acid The new compounds can be present, depending on the choice o~ starting materials and working procedures, , . ", . ~ . , . ~ .....

, as optical antipodes or racemates or, if they have at least two asymmetric carbon atoms, also as mixtures of isomers (racemate mixtures). The mixtures of isomers (racemate mixtures) obtained can, by virtue of the physical-chemical differences in the constituents, be separated in a known manner into the two stereoisomeric (diastereomeric) pure racemates, e.g. by chromatography and/or fractional crystallisation.

Resulting racemates can be resolved by known methodæ, for example by recrystallisation from an optically active solvent, with the aid of microorganisms, or by reaction with an optically active acid forming salts with the racemic compound, and separation of the salts obtained in this manner, e.g. by virtue of their difIerent degrees of solubility, into the diastereomers from which the an~ipodes can be libera~ed by the action of suitable agen~. Particularly suitable optically active acids are, for example, the D- and L-forms of tartaric acid, di-o-toluyltartaric acid, malic acid, rnandelic acid, camphor-sulphonic acid or ~uinic acid. It is of advantage toisolate the more effective of the two antipodes.

The new compounds are administered oral1y, rectally or parenterally. The dosage amount depends on the mode 1~74313 of administration, on the species, on the age and on the individual condition. The daily doses of the free bases or of pharmaceutically acceptable salts thereof vary between 0.1 mg/kg and 3 mg/kg for warm-blooded animals. Suitable dosage units, such as dragées, tablets, suppositories or ampoules, preferably contain 0.5 - 50 mg of an active substance according to the invention.

Dosage units for oral administration contain as active substance preferably between 0.5 and 50% of a compound o~ the general formula I, or of a pharmaceutically acceptable salt thereof. The said dosage units are produced by combination of the active substance with, e.g., solid pulverulent carriers such as lactose, saccharose, sorbitol or mannitol; starches such as pota~o starch, maiæe s~arch or amylopectin, also laminaria po~del^ or citru~ pulp powder; cellulose deriva~ives or gelatine, optionally with the addition of lubricants, such as magnesium or calcium stearate or polyethylene glycols, to form tablets or dragée cores. The dragée cores are coated, ~or example, with concentrated s-lgar solutions which can also contain, e.g., gu~ arabic, talcu:n and/or titanium dioxide, or with a lac4uer ~issolved in readily volatlle crganic solvents OL- solvent mix~ures.

'' '~;~ ' ' ` .

1~74313 Dyestuffs may be added to these coatings, e.g. for identification of the various dosage amounts.

Furth~r sui~able oral dosage units are hard gelatine capsules, as well as soft closed capsu]es made from gelatine and a softener such as glycerin. The hard gelatine capsuLes contain the active substance preferably as a granulate, e.g. in admixture with fillers such as maize starch, and/or lubricants such as talcum or magnesium stearate, and optionally stabilisers such as sodium metabisulphite (Na2S205) or ascorbic acid. In soft capsules, the active substance is preferably ~ssolved or suspended in suitable liquids, such as in polyethylene glycols, to which likewise stabilisers may be added.

15 ~ Suitable dosage units ~or rectal administration are, e.g., ~uppositories consisting of a combinution of an active substance with a suppository foundation substance.
Applicable suppository foundation substances are, e.g., natural or synthetic triglycerides, paraffin hydrocarbons, polyethylene glycols or higher alkanols. Also suitable are gelatine rectal capsules consisting of a combination of the ac~ive substance wi~h a foundatlon substance.

Suitable foundation subs~ances are, e.g., liquid ~ri-glycerides, polyethylene glycols or paraffin hydrocarbons.

Ampoules for parenteral administration, especially intramuscular administration, preferably contain a water-soluble salt of an active substance in a concentration preferably of 0.2 - 5%, optionally together with suitable stabilisers and buffer substances~ in aqueous solution.

The following working examples further illustrate the production of tablets, dragées, suppositories and ampoules:
a) 50.0 g of 1-12-(o-chlorobenzoyl)-4-chlorophenyl~-5-(morpholinornethyl)-lH-1,2,4-triazole-3-carboxamide is mixed with 500 g of lactose and 292 g of potato starch;
the mixture is moistened with an alcoholic solution of ~5 ~ g of gelatine, and then granulated through a sieve.
Af~er drying o~ the granulate, 60 g of potato starch, 60 g of talcum, 10 g of magnesium stearate and 20 g of highly dispersed silicon dioxide are mixed in, and the mixture is subsequently pressed out to form 10,000 tablets each A ~20 weighing 105.0 mg and each containing 5.0 mg of active substance; the tablets can be provided with grooves to effect a more precise adjustment of the dosag~ amount.

:
' lV74313 b) 2.50 g of N,N-dimethyl~ 2-(o-fluorobenzoyl)-4-chlorophenyl]-S-(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxamide is well mixed with 15 g of maize starch and 6 g of highly dispersed silicon dioxide. ThP mixture is moistened with a solution o~
2 g of stearic acid, 6 g of ethylcellulose and 6 g of stearin in about 70 ml of isopropyl alcohol, and is then granulated through a sieve III (Ph.~l~lv. V). The granulate is dried for about 14 hours and is subsequel~tly put through sieve III-lIIa. It is then mixed with 16 g of maize starch, 16 g of talcum and 2 g of magnesium stearate and the mixture is pressed out to form 1000 dragée cores.
These are coated with a concentrated syrup of 2 g of lacca, 7.5 g of gum arabic, 0.15 g of dyestuff, 2 g of highly dispersed silicon dioxide, 25 g of talcum and 53.35 g o sugar, and finall.y dried. The dra&ées obtained each weigh 162.5 mg and each contain 2.5 mg of active substance.

c) 10.0 g of 1-l2-(o-chlorobenzoyl)-4-chlorophenyl]-5-(morpholinomethyl)-lH-1,2,4-triazole-3-carboxamide and 1990 g of finely ground suppository foundation subst~nce (e.g. cocoa butter) ~re thoroughly mixed and then melted. From the melt, maintained homogeneo~s by stirring, - ~5 -'' ':, `, , , ,:

i~74;~13 there are formed 1000 suppositories each weighing 2 g and each containing 10 mg of active substance.

d) A solution of 5.0 g of 1-[2-(o-chlorobenzoyl)-4-chlorophenyl]-3,5-bis-[(dimethylamino)-methyl]-lH-1,2,4-triazole-dihydrochloride in one litre of water is filled into 1000 ampoules and sterilised. Each ampoule contains 5 mg of active substance as a 0.5%
solution.

The following examples further illustrate the production of the new compounds of the general formula I
as well as of starting materials not hitherto known, but t~ey are not intended to limit in any way the scope of the invention. Temperatures are given in degrees Centigrade.

Example 1 A mixt:ure o~ 8.~ g (0.018 mole) of 1-(2-benzoyl-
4-clllorophenyl)-5-(iodomethyl)-lH-1,2,4-triazole-3-carboxylic acid methyl ester and 3.5 ml (0.040 mole) of morpholine are stirred in 175 ml of methanol at 40 S for 6 hours. The reaction mixture is thereupon concentrated in vacuo, water is added to the residue, and extraction is performed twice with methylene chloride. The organic phase is washed three times with water and once with saturated sodium chloride solution; it is dried over sodium sulphate and concentrated in vacuo. The residue is triturated ~ith ether, whereupon the reaction product is ohtained in crystalline form. After filtration with suction and drying in vacuo, there is obtained 1-(2-benzoyl-4-chlorophenyl)-S-(morpholinomethyl)-lH-I~ 1.,2,4-tria~ole-3-carboxylic acid methyl ester, m.p. 165-170'.

'rhe startin~ material is produced as follows:

a) 224 ml o~ a 6N solution of hydrogen chloride in methanol is added to a solution of 112.2 g (0.299 mole) of 1-(2-benzoyl-4-chlorophenyl)-S-(chloromethyl)-lH-1,2,4-triazole-3~carboxylic acid in 1120 ml of methanol, and the whole is refluxed for 21 hours. There is then distilled ~' '` ,. "
.

10743~3 off 800 ml of methanol at normal pressure, and the concentrated solution is allowed to stand for 18 hours at room temperature. The product that has crystallised out is filtered off under suction and washed with cold methanol and hexane. After drying in vacuo, there is obtained l-(2-benzoyl-4-chlorophenyl)-5-(chloromethyl)-lH-1,2,4-triazole-3-carboxylic acid methyl ester, m.p. 132-134~.

b) A solution o~ 51.6 g (0.132 mole) of 1-(2-benzoyl-4-chlorophenyl)-5-(chloromethyl)-LH-1,2,4-triazole-3-carboxylic acid methyl ester and 29.8 g (0.198 mole) of sodium iodide in 1000 ml of acetone is refluxed for 45 minutes. The reaction mixture is thereupon concentrated in vacuo. Water is added to the residue and extraction is perormed twice with methylene chloride. The organic phase is washed once with diluted aqueous sodi~m bisulphite solution and twice with saturated sodium chloride solution; it is dried over sodium sulphate and concentrated in vacuo. The residue is triturated with ether, whereupon the reaction product crystallises ou~.
After filtration under suction and drying in vacuo, there is obtained 1-(2-benzoyl-4-chlorophenyl)-5-(iodomethyl)-lH-1,2,4-triazole-3-carboxylic acid methyl ester, m.p. 139-142~.

.
"' ~ "' '-1~74313 Example 2 A mixture of 24.0 g (0.050 mole) of 1-(2-benzoyl-4-chloropl7enyl)-5-(iodomethyl)-lH-1,2,4-triazole-3-carboxylic acid methyl ester ~see Example la) and b)~
and 20.5 ml of 33% ethanolic dimethylamine solution in 480 ml of methanol is stirred for 2 hours at room temperature. The reaction solution is thereupon concentrated in vacuo; water is added to the residue and extraction is performed twice with methylene chloride. The organic phase is washed twice with ~ater 1~ and once with saturated sodium chloride solution; it is dried over sodium sulphate and concentrated in vacuo to dryness. The amorphous residue is dissolved in 150 ml o~
ether. The reaction product crystallises out whilst the solution is allowed to stand. The reaction product is fill:ered off under suc~ion and washed with ether. After dryin~, there is obtained 1-(2-benzoyl-4-chlorophenyl)-5-¦(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxyl~c acid methyl ester, m.p. 118-121.

Example 3 To the solution of 6.0 g (0.0203 mole) of 6-phenyl-8-chloro-4H-s-triazolo[1,5-a][1,4]benzodiazepine (see German 'Offenle~ungsschrift' No. 2,159,527) in 27 ml of 85% formic acid there is added 13.7 ml of 36%
~ueous formaldehyde solution, and the mixture is heated, with stirring, for 2 hours at 100. The reaction solution is then allowed to cool to room temperature;
it is poured into ice water, and concentrated sodium hydroxide solution is added until the pH-value has reached 11. The precipitated crude product is taken up in ether. The organic phase is washed twice with water and once with saturated sodium chloride solution; it is dried over sodium sulphate and concentrated in vacuo.
The residue is dissolved in 100 ml of ethyl acetate, and ~thereal hydrochlorie acid solution is added until the pH has reached a value of 3. The hydrochloride precipitates out in crystallille form. It is filtered off with suction after 2 hours and wàshed with ether and hexane. There is obtained 1-(2-benzoyl-4-chlorophenyl)-5-[(dimethylamino)~
methyl]-lH-1,2,4-triazole hydrochloride, m.p. 182-18 with decomposition.

: - .

-.

1~74313 Example 4 13.5 ml of 85% formic acid and 6.7 ml of 36% asueous formaldehyde solution are added to 3.4 g (0.001 mole) of ~-phenyl-8-chloro-4H-s-triazolo[1,5-a][1,4]benzo-diazepine-2-carboxylic acid (see German 'Offenlegungs-schriften' ~os. 2,159~527 and 2,215,943). The reaction mixture is subsequently heated, with stirring, at lO0 for 2 hours, in which time the starting product goes completely into solution. A~ter cooling, there is added concentrated sodium hydroxide solution until the pH has reached a value of 5, and the mixture is concentrated in vacuo to dryness. In order to obtain complete drying, the residue is concentrated a further three times with a mixture of toluene/methanol (1:1) in vacuo at 60. The residue is ex~racted th~ee times with boiling methylene chloride. The organic phase is concentrated in vacuo, and the residue is dissolved in 300 ml of ethyl acetate.
The cloudy solu~ion is treated with charcoal and filtel-ed through Hyflo. A solution of hydrogen chloride in ether is added to the clear filtrate until an acid reaction to 2G Congo red is indicated. The precipitated crystals are i]ltered with suction and washed with ethyl ace~ate and ether. There is obtained 1-(2-benzoyl-4-chlorophenyl)-5-' , '' .

1~74313 1(dimethylamino)-methyl]-lH-1~2~4-triazole-3-carboxylic acid hydrochloride, m.p. 160-165 with decomposition.
The following are obtained in an analogous manner:
from 3.25 g (0.001 mole) of 6-phenyl-8-chloro-4H-s-triazolo[l,5-a3[1,43benzodiazepine-2-methanol:- 1-(2-benzoyl-4-chlorophenyl~-5-[(dimethylamino~-methyl]-lH-1,2,4-triazole-3-methanol-hydrochloride;
from 3.43 g (0.001 mole) of 6-(o-fluorophenyl~-8-chloro-4H-s-triazolo[1,5-a][1,4]benzodiazepine-2-methanol:-1-[2-(o-fluorobenzoyl)-4-chlorophenyl~-5-[(dimethylamino)-methyl]-lH-1,2,4-triazole-3-methanol-hydrochloride; and from 3.59 ~ (0.001 mole) of 6-(o-chlorophenyl)-8-chloro-4H-s-triaæolo[l,5-a][1,4]benzodiazepine-2-methanol:- 1-[2-(o-chlorobenzoyl)-4-chlorophenyl]-5-[(dimethylamino)-methyl]-lS 1,2,4-tri~ole-3-methanol-hydrochloride.

The production of the starting materials is described in the German 'Offenlegungsschrift' No. 2,234,652.

1C~74313 Example 5 35 ml of 36% aqueous formaldehyde solution is added ~o the solution of 19.2 g (0.050 mole) of N,N-dimethyl-6-(o-fluorophenyl)-8-chloro-4H-s-triazololl,5-a][1,4]
benzodiazepine-2-carboxamide (see German 'Ofenlegungs-schrift' No. 2,304,307) in 68 ml of 85% formic acid, and the mixture is heated with stirring for 2 hours at 100. The reaction mixture is afterwards cooled to room temperature; it is poured into ice water, and concentr~ted sodium hydroYide solution is added until the pH-value reaches 11. The precipitated crude product is taken up in methylene chloride. The methylene chloride solution is washed twice with water and once with saturated sodium chloride solution; it is dried over sodium sulphate and concentrated in vacuo. The residue is recrystallised ~rom isopropanol and, after drying in vacuo, there is ~btained N,N-dimèthyl-1-[2-(o-fluorobenæoyl)-4-chlorophen~l]-S-l(dimethyla.nino)-methyl]-lH-1,2,4-triazole-3-czrboxamidc, m.p. 140-L42.

The following are obtained in an analogous manner:

from 20.6 g of N,N-diethyl-6-(o-fluorophenyl)-8-chloro-4H-s-triazolo[1,5-a~[1,4]benæodiazepine-2-carboxamide:

'.' .:

, 1~74313 N,N-diethyl-l-L2-(o-fluorobenzoyl)-4-chlorophenyl]-5-¦(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxamide;

from 20.0 g of N,N-dimethyl-6-(o-chlorophenyl)-8-chloro-4H-s-triazololl,5-a~[1,4~benzodiazepine-2-carboxamide:-N,N-dimethyl-1-l2-(o-chlorobenzoyl)-4-chlorophenyl~-5-l(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxamide;

from 21.4 g of N,N-diethyl-6-(o-chlorophenyl)-8-chloro~
4H-s-triazolo~1,5-a]11,4]benzodiazepine-2-carboxamide:-N,N-diethyl-1-~2-(o-chlorobenzoyl)-4-chlorophenyl]-5-[(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxamidc;

~rom 18.3 g of N,N-dimethyl-6-phenyl-8-chloro-4H-s-triazolo ~ -a][l~4]benzodiazepine-2-carboxamide:- N,N-dimethyl-l-(2-benzoyl-4-chlorophenyl)-5-l(dimethylamino)-methyl]-lH-. 1,2,4-triazole-3-carboxamide, from 19.7 g of N,N-diethyl-6-phenyl-8-chloro-4H-s-triazolo 1l~5-a][l~4]benzodiazepine-2-carboxamide:- N,~-diethyl-l-(2-benzoyl-4-chlorophenyl)-5-l(dimethylamino)-methyl]-lH-1~2,4-triazole-3-carboxamide;

from 20.0 g of N,N-dimethyl-6-phenyl-8-(trifluoromethyl)-411-s-triazololl.,5-a][1,4]benzodiazepine-2-carboxamide:-1~74313 N,N-dimethyl-1-(2-benzoyl-~ a-trifluoro-p-tolyl)-5-[(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxamide;

rom 18.8 g of N,N-dimethyl-6-phenyl-8-nitro-4H-s-triazolo[l,5-a~11,4]benzodiazepine 2-carboxamide:-N,N-dimethyl-1-~2-benzoyl-4-nitrophenyl)-5-[(dimethyl-amino)-methyl]-lH-1,2,4-triazole-3-carbox&mide;

from 19.7 g of N,N-dimethyl-6-(o-fluorophenyl)-8-nitro-4H-s-triazolo[l,S-a][1,4]benzodiazepine-2-carboxamide:-N,N-dimethyl-1-~2-(o-fluorobenzoyl)-4-nitrophenyl]-5-~(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxamide;

from 16.9 g of 6-phenyl-8-chloro-4H-s-triazolo[1,5-a~[1,4]
benzodiazepine-2-carboxamide:- 1-(2-benzoyl-4-chiorophenyl)-
5-L(dirnethylamino)-methyl]-lH-l~2~4-triazole-3-carboxalnide;

from 18.6 g of 6-(o-chlorophen.yl)-8-chloro-4H-s-triazolo lS l].,S-a]l1,4]benzocli.azepine-2-carboxarnide:- 1-L2-(o-chlorobenzoyl)-4-chlorophenyl]-5-[(dimethylamino)-methyll-1}1-1,2,4-triazole-3-carboxamide;

from 17.8 g of 6-(o-fluorophenyl)-8-chloro-4~-s-triazolo [1,5-a] L 1,4]benzodiazepine~2-carboxamide:- 1-l2-(o-fluorobenzoy])-4-chlorophenyl]-5-~(dimethylamina)-methyl~
lH-1,2,4-triazole-3-carboxarnide;

' . : . , ~ . ~ , 1~74313 from 18.5 g of N-methyl-6-(o-fluorophenyl)-8-chloro-4H-s-triazolo[1,5-a]Ll,4]benzodiazepine-2-carboxamide:-N-methyl-1-[2-(o-fluorobenzoyl)-4-chlorophenyl]-S-[(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxamide;

from 19.3 g of N-methyl-6-(o-chlorophenyl)-8-chloro-4H-s-triazolo[l,5-a]11,4]benzodiazepine-2-carboxamide:-N-methyl-1-[2-(o-chlorobenzoyl)-4-chlorophenyl]-5-¦(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxamicle;

from 19.2 ~ of N-ethyl-6-(o-fluorophenyl~-8-chloro-4H-s-triazololl,5-a][1,4]benzodiazepine-2-carboxamide:-N-ethyl-1-[2-(o-fluorobenzoyl)-4-chlorophenyl]-5-[(dimethyl-amino)-methyl]-lH-1,2,4-triazole-3-carboxamide;

~rom 19.9 g of N-isop~~opyl-6-(o-fluorophenyl)-8-chloro-. 4H~s-tria~ole [ 1, 5-a ] 11, 4]benzodiazepine-2-carboxamide:-N-isopropyl-1-¦2-(o fluorobenzoyl)-4-chloropherlyl]-5-I(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxamide;

from 21.3 g of 4-[l6-(o-fluorophenyl)-8-chloro-4H-s-triazololl,5-a][1,4]benzodiazepin-2-yl]-carbonyll-morpholine:-4-[[1-~2-(o-fluoroben.zoyl)-4-chlorophenyl]-~-[(dimethyl-amino)-metllyll-lH-l~2~4-triazol-3-yll-carbonyl~-morpholine;

. , . -.. ,. ~ .

1~74313 from 20.5 g of 1-~[6-(o-fluorophenyl)-8-chloro-4H-s-triazolo[l,S-a][1,4Jbenzodiazepin-2-yl]-carbonyl]-pyrrolidine~ l[l-[2-(o-fluorobenzoyl)-4-chlorophenyl]-5-l(dime~hylamino)-methyl3-lH-1,2,4-triazol-3-yl]-carbonyl]-pyrrolidine;

from 21.2 g of 1-[L6-(o-fluorophenyl)-8-chloro-4H-s-triazololl,5-a][1,4]benzodiazepin-2-yl~-carbonyl]-piperidine:- l-[[l-12~(o-fluorobenzoyl)-4-chlorophenyl~-5-l(dimethylamino)-methyl]-lH-1,2,4-triazol-3-yl]-carbonyl]-piperidine;

from the base liberated from 23.8 g (O.OSO mole) of 1-1[6~(o-fluorophenyl)-8-chloro-4H-s-triazololl,5-a][1,4]
benæodiazepin-2-yl]-carbonyl]-4-methylpiperazine hydrochloride:- 1-1[1-{2-(o-fluorobenzoyl)-4-chlorophenyl]-s-l(dinlethylamino)-me~hyl]-lH-l~2~4-triazol-3-yl]-carbonyl]-4-methylpiperazine and tne dihydrochloride thereof.

The starting materials used are descri~ed in the German 'Offenlegungsschrift' No. 2,304,307.

-:

. -. ~..
`
- .

1~74313 Example 6 8.35 ml (about 0.10 mole) of 36% aqueous formaldehyde solution is added to the solution of the base, liberated irom ~.30 g (0.010 mole) of 2-[(methylamino)-methyl]~6-(o-chlorophenyl)-8-chloro-4H-s-triazolo[1,5-a][1,4]benzo-diazepine-fumarate-(2:1) (see German 'O~fenlegungsschrift' No. 2,234,652), in 13.5 ml (about 0.25 mole) o~ 85% formlc a~id, and the mixture is heated, with stirring, for 2 hours at 100. The reaction solution is afterwards cooled to room temperature; it is poured into ice water, and concentrated sodium hydroxide solution is added until the pH-value has reached 11. The crude product that has precipitated is taken up in ether. The organic phase is washed twice with water and once with saturated sodium chloride solution; it is dried ovcr ~odiùm sulphate and then concentrated in vacuo.
~1he oily residue is dissolved in 100 ml of ethanol, and ethereal hydrogen chloride s~lution is added until the pl~-~alue has reached 2. The ethanol is thereupon completely distilled off in vacuo, and ethyl acetate is added to the residue. The product obtained in crystalline form is filteL-ed with suction and washed with ethyl acetate and ether. After drying in vacuum, there is obtained 1-[2-(o-chlorobenzoyl)-4-chlorophenyl3-3,5-bis-(dimethyl-' ' :
'.

1~74313 amino)-methyl]-lH-1,2,4-triazole-dihydrochloride, m.p. 100-105 with decomposition.
The following are obtained in an analogous manner:

from the base liberated from 4.30 g (0.010 mole) of 2~ nethylamino)-methyl]-6-(o-fluorophenyl)-8-chloro-4H-s-triazolo[l,5-a][1,43benzodiazepine-hydrochloride-dihydrate:-1-[2-(o-fluorobenzoyl)-4-chlorophenyl]-3,5-bis-[(dimethyl-amino)-methyl3-lH-1,2,4-triazole and the dihydrochloride thereof.

The following are obtained likewise analogously but, if desired, with reduction of the amount of 36%
formaldehycle solution to 5.85 ml (about 0.07 mole):

frorn 3.52 g (0.010 mole) of 2-[(dimethylamino)-methyl]-6-phenyl-8-chloro-4H-s-triazolo[1,5-a][1,4]benzodiazepine:-lS 1~(2-b~llæoyl-4-chlorophenyl)-3,5-bis-[(dimethylamino)-me~hyl]-ll-l-1,2,4-triazole and the dihydrochloride thereof;

from 3.~2 g (0.010 mole) of 2-(piperidinomethyl)-6-phenyl-~-chloro-4H-s-triazolo[1,5-a][1,4]benzodiazepine:-1-(2-benzoyl-4-chlorophenyl)-3-(piperidinomethyl)-5-[(dimethylamino)-me~hyl3-lH-1,2,4-triazole and the dillydrochloride ~hereof;

~ ~', - .,' `

from 3.78 g (0.010 mole) of 2~ pyrrolidinyl)-methyl~-
6-phenyl-8-chloro-4H-s-triazolo[1,5-a]11,4]benzodiazepine:-1-(2-benzoyl-4-chlorophenyl)-3-[(1-pyrrolidinyl)-methyl]
-S-[(dimethyl.amino)-methyl~-lH-1,2,4-triazole and the dihydrochloride thereof;

from 3.94 g (0.010 mole) of 2-(morpholinomethyl)-6-phenyl-8-chloro-4H-s-triazolo[1,5-a]l1,4]benzodiazepine:-1-(2-benzoyl-4-chlorophenyl)-3-(morpholinomethyl)-5-l(dimethylamino)-methyl]-lH-1,2,4-triazole and the dihydrochloride thereof; and from 4.07 g (0.010 mole) of 2-[(4-methyl-1-piperazinyl)-methyl]-6-phenyl-8-chloro-4H-s-triazolo[1,5-a)11,4]
benzodiazepine:- l-(2-benzoyl-4-chlorophenyl)-3-[(4-methyl-l-piperazinyl)-methyl~-5-[(dimethylamino)-methyl)-lH-1,2,4-triazole and the trihydrochloride therPof.

The starting materials used are described in the ; German ' Off enlegungsschrift' No. 2,234,65Z.

:.
"' . :, .: ~ .. . ...

: , . . . .
- - : . .;
.
. .

Example 7
7.6 g (0.017 mole) of 1-(2-benzoyl-4-chlorophenyl)-5-(morpholinomethyl)-lH-1,2,4-triazole-3-carboxylic acid methyl ester (see Example 1) is covered over with 340 ml of methanol and 69 ml of concentrated aqueous ammonia solution. The mixture is heated, with stirring, for 4 hours at 40, with the starting material slowly going into solution. The reaction mixture is then allowed to stand for 18 hours at room temperature, and subsequently concentrated in vacuo. Water is added to the residue and extraction is performed twice with methylene chloride.
The organic phase is washed twice with ice-cold lN
sodium bicarbonate solution, once with water and once with saturated sodium chloride solution; it is dried over sodium æulphate and then concentrated in vacuo to dryness. The residue is recrystallised from isopropanol to obtain, after drying in vacuum, 1-(2-benzoyl-4-chlorophenyl)-5-(morpholinomethyl)-lH-1,2,4-triazole~3-~ carboxamide, m.p. 146-149.

.
.

- , . , . . - . ,. :
~. , . ., :: . . , : : ''~ , . : .
: ;, . ~ - ,.
,, ;j :
. .
.. . .

10743~3 Example 8 17.5 g (0.044 mole) of 1-(2-benzoyl-4-chlorophenyl)-5-[(dimethylamino)~methyl]-lH-1,2,4-triazole-3-carboxylic acid methyl ester (see Example 2) is covered over with 850 ml of methanol and 175 ml of concentrated aqueous ammonia solution. The reaction solution is stirred for 7 hours at room temperature, and afterwards concentrated in vacuo to dryness. Water is added to the residue, and extraction is performed twice with methylene chloride.
The organic phase is washed twice with water and once with saturated sodium chloride solution; it is dried over sodium sulphate and concentrated in vacuo to dryness.
The residue is dissolved in 300 ml of ethyl acetate, and ethereal hydrogen chloride solution is added until the pH-value has reached 2. The crystalline product is filtered with su~tion and washed with ethyl acetate and ;` ether. After drying in vacuum, there is obtained 1-(2-benzoyl-4-chlorophenyl)-S-[(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxamide-hydrochloride, m.p. 250-255 with decomposition.
. ' ." ' .

' . .,, . ! ' ' Example 9 9.00 g (0.018 mole) of crude 1-[2-(o-chlorobenzoyl)-4-chlorophenyl3-5-(morpholinomethyl)-lH-1,2,4-triazole-3-carboxylic acid hydrochloride is refluxed with 90 ml of thionyl chloride for 90 minutes. The clear solution is concentrated in vacuo at 40~ and the residue, in order to completely remove the thionyl chloride therefrom, is dissolved in 100 ml of absolute toluene and again concentrated by evaporation.

The crude acid chloride hydrochloride is covered over with 90 ml of concentrated aqueous ammonia solution and the whole is stirred for 18 hours at room temperatllre.
The reaction mixture is afterwards cooled for 2 hours with ice water; the precipitated crude product is filtered off, and then well washed with cold water. After ;~ lS recrystallisation from isopropanol there is obtained 1-l2-(o-chlorobenzoyl)-4-chlorophenyl]-5-(morpholinomethyl)-lH-1,2,4-~riazole-3-carboxamide, m.p. 165-167.

The starting material is produced as ~ollows:

a) 0.10 g of sodium iodide is added to a mixture of 9.3 g (0.0226 mole) of 1-[2-(o-chlorobenzoyl)-4-chloro-phenyl]-5-(chloromethyl)-1~l-1,2,4-triazolP-3-carboxylic acid ,. .~ , . .
.

1~74313 (see German 'Offenlegungsschrift' No. 2,159,527, page 32) and 9.5 g (O.ll mole) of morpholine in 100 ml of ethanol, and the whole is refluxed for 2 hours. The reaction mixture is thereupon concentrated in vacuo; the residue is dissolved in water, and 2N hydrochloric acid is added until an acid reaction to Congo red is obtained.
The precipitated hydrochloride of the reaction product is extracted twice with 100 ml of methylene chloride each time. A~ter washing with saturated sodium chloride solution, drying over sodium sulphate and concentration by evaporation, the organic extracts yield 1-12-(o-chlorobenzoyl)-4-chlorophenyl]-5-(morpholinomethyl)-lH-1,2,4-triazole-3-carboxylic acid hydrochloride in the form of an amorphous yellow foam, which is used directly ~or the next step.

' - ~4 -,, .

.
.

-Example 10 The following are obtained analogously to Example 7:

starting with 7.3 g (about 0.017 mole) of crude 1-(2-benzoyl-4-chlorophenyl)-5-[(1-pyrrolidinyl)-methyl]-lH-1,2,4-~riazole-3-carboxylic acid methyl ester:- amorphous 1-(2~benzoyl-4-chlorophenyl)-5-[(L-pyrrolidinyl)-methyl]-lH-1,2,4 triazole-3-carboxamide, of which the hydrochloride, prepared with ethereal hydrogen chloride solution in ethyl acetate, melts at 236~ (with decomposition) after recrystallisation from isopropanol; and starting with 7.5 g (about 0.017 mole) of crude 1-(2-benzoyl-4-chlorophenyl)-5-(piperidinomethyl)-lH-1,2,4-triazole-3-carboxylic acid methyl ester:- crude 1-(2-benzoyl-4-chlorophenyl)-5-(piperidinomethyl)-lH-1,2,4-~riazole-3-carboxamide, of which the analogously prepared hydrochloride melts at 255-260 (with decomposition) ater recrystallisation from isopropanol.
The starting materials are produced as ~ollows:

a) By a procedure analogous to that of Example 1 there are obtained, with the use of 2.9 g (0.041 mole) of pyrrolidine and 3.0 g (0.041 mole) of piperidine, instead of morpholine, crude l-(2-benzoyl-4-chlorophenyl)-.; . , . ~ ."., .............. .:,,: :;..... -., -. ,. . ~
- :, : .

S-~(l-pyrrolidinyl)-methyl]-lH-1,2,4-triazole-3-carboxylic acid methyl ester and crude 1-(2-benzoyl-4-chlorophenyl)-5-(piperidinomethyl)-lH-1,2,4-triazole-3-carboxylic acid methyl ester, respectively.

'' :
,...
.:, : - 66 -. . ~
- . .
: . , : - .. .
.. ; . . . . - , -. . .

Example 11 7.0 g (0.0165 mole) of crude 1-(2-benzoyl-4-ni ro-phenyl)-5-L(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxylic acid ethyl ester (see below) is covered over with 200 ml of ethanol and 20 ml of conc~ntrated aqueous S ammonia solutionO The reaction mix~ure is allowed to stand for 3 days at room temperature, and is then concentrated in vacuo. Water is added to the residue and extraction is performed twice with ethyl acetate The organic phase is washed twice with cold lN sodium bicarbonate solution and twice with saturated sodium chloride ~olution; i~ is dried over sodium sulphate and concentrated in vacuo to dryness. The residue is dissolved in ethyl acetate/isopropanol (5:1), and the solution is chrom~tographed on a column of 150 g of silica gel. The lS eluting agent employed is ethyl acetate/isopropanol (5:1).
The fractions containing the desired product are combined, and concentrated by evaporation. The residue is recrystal-lised from ethanol to obtain, after drying in vacuum, 1-(2-benzoyl-4-nitrophenyl) 5-[(dimethylamino)-methyll-lH-1,2,4-triazole-3-carboxamide, m.p. 187-190.

There is obtained in an analogous m.anner, with the use of 7.3 g (0.016~ mole) of crude 1-~2-(o-fluorobenzoyl)-.

: - . . , ... . . .. ..
.. .. .. . .

1~74313 4-nitrophenyl]-5-l(dimethylamino)-methyl~-lH-1,2,4-triazole-3~carboxylic acid ethyl ester (see below):
1-l2-(o-fluorobenzoyl)-4-nitrophenyl]-5-[(dimethyl-amino)-methyl]-lH-1,2,4-triazole-3-carboxamide.

The starting materials are produced as follows:
. .
6 ml (0.072 mole) of 36% aqueous formaldehyde solution is added to the solution of 7.55 g (0.020 mole) of 6-phenyl-
8-nitro-4H-s-triazolo[1,5-a]~1,4]benzodiazepine-2-carboxylic acid ethyl ester (see German 'Offenlegungs-schri~t' No. 2,304,307) in 50 ml of 85% formic acid, and the mixture is heated for 2 hours at 100. The reaction mixture is afterwards poured into 200 ml of ice water, and an undissolved yellow by-product is separated by filtration through purified diatomaceous earth. Sodium carbonate is added to the filtrate, with ice cooling, until the pH-value has reached 9, and extraction is performed twice with ethyl acetate. The organic phase is washed twice with water and once with saturated sodium chloride solution; it is dried over sodium sulphate and concentrated in vacuo. The residue contains 1-(2-benzoyl-4-nitrophenyl)-s-[(dimethylamino)-methyl]-lH-l~2~4-triazole 3-carboxylic acid ethyl ester as viscous oil, which is used directly for ammonol6y8sis.

.
- . , , . .. ~ .
, - -, ,, -,. - . . ,, : : . . -,, - . .

1~743~3 There is obtained in an analogous manner, starting with 7.91 g (0.020 mole) of 6-(o-fluorophenyl)-8-nitro-4H-s-triazolo[1,5-a][1,4~benzodiazepine-2-carboxylic acid ethyl ester, described in the same 'Offenlegungsschrift', 1-[2-(o-fluorobenzoyl)-4-- nitrophenyl)-5-[(dimethylamino)-methyl]-lH-1,2,4-~ triazole-3-carboxylic acid ethyl ester.

", ~:' . -lV74313 E~xample 12 4.0 ml of 33/0 ethanolic dimethylamine solution is added to a mixture of 3.75 g (0.01 mole) of 1-(2-benzoyl-4-chlorophenyl)-5-(chloromethyl)-lH-1,2,4-triazole-3-carboxamide and 0.15 g of sodium iodide in 70 ml of ; S methanol, and the whole is refluxed for 4 hours with stirring. The reaction mixture is subsequently concentrated in vacuo. Water and saturated sodium carbonate solution - are added until the pH-value has reached 10, and extraction is performed twice with ethyl acetate. The organic phase is washed twice with water and once with saturated sodiurn chloride solution; it is then dried over magnesium sulphate and filtered. To the filtrate there is added etllereal hydrogen chloride solution until the pH-value haY reached 3. The product precipitating in crystalline form is filtered off with suction and washed with ethyl acetate and ether. After drying in vacuum, there is obtained 1-(2-benzoyl-4-chlorophenyl)-5-[(dimethyl-amino)-methyl]-lH-1,2,4-triazole-3-carboxamide-hydrochloride, m.p. 250 with decomposition.

The starting material is produced as follows:

a) 30 ml of concentrated aqueous ammonia solution is , . ~ ,.: , ,,...,- . . .... .. .
,, - - ,.,, " ,, , ::
: : -- :

added dropwise at 30 in the course of 5 minutes, with stirring, to the suspension of 6.0 g (0.015 mole) of 1-(2-benzoyl-4-chlorophenyl)-5-(chloromethyl)-lH-1,2,4-triazole-3-carboxylic acid methyl ester in 220 ml 5 of methanol. There has formed after 4 hours a clear reac~ion solution, and a short time later a crystalline product commences to precipitate. Stirring is maintained for one hour at room temperature and for one hour at 0-5. The formed crystals are thereupon filtered off and L0 recrystallised from 50 ml of methanol. The product is filtered off with suction and washed with methanol and hexane. After drying in vacuum, there is obtained 1-(2-benzoyl-4-chlorophenyl)-5-(chloromethyl)-lH-1,2,4-triazole-3-carboxamide, m.p. 128-130.

., . : . . `

1~74313 Example 13 A mixture of 38.7 g (0.075 mole) of 1-[2-(o-ch;oro-benzoyl)-4-chlorophenyl]-5-(iodomethyl)-lH-1,2,4-triazole-3-carboxylic acid methyl ester and 13.1 g (O.lSO mole) of morpholine in 750 ml of methanol is stirred for 8 hours at 40. The reaction mixture is then concentrated in vacuo; water is added to the residue and extraction is performed twice with methylene chloride.
The organic phase is washed three times with water and twice with saturated sodium chloride solution; it is dried over sodium sulphate and concentrated in vacuo. The residue is triturated with ether, whereupon the reaction product is obtained in crystalline form. After filtration with suction and drying in vacuum, there is obtained 1-l2-(o-chlorobenzoyl)-4-chlorophenyl]-5-(morpholinomethyl)-lH-1,2,4-triazole-3-car~oxylic acid methyl ester, m.p. 141-143.

The following are obtained in an analogous manner:

with the use of 10.7 g (0.15 mole) of pyrrolidine there is yielded 1-12-(o-chlorobenzoyl)-4-chlorophenyl3-5-l(l-pyrrolidinyl)-methyll-lH-1,2,4-triazole-3-carboxylic acid methyl ester;

,, ~ ., ~ . ' i~74313 with the use of 12.8 g (0.15 mole) of piperidine there is ; yielded 1 12-(o~chlorobenzoyl)-4-chlorophenyl]-5-(piperidinomethyl)-lH-1,2,4-triazole-3-carboxylic acid methyl ester, and with the use of 11.0 g (0.15 mole) of diethylamine there is yielded 1-[2-(o-chlorobenzoyl)-4-chlorophenyl)-5-l(diethylamino)-methyl]-lH-1,2,4-triazole-3-carboxylic acid methyl ester.

The 1-l2-(o-chlorobenzoyl)-4-chlorophenyl)-5-(iodomethyl)-lH-1,2,4-triazole-3-carboxylic acid methyl ester required as starting material is produced as follows:

a) 270 ml of a 6N solution of hydrogen chloride in methanol is added to a solution of 133.0 g (0.30 mole) of 1-l2-(o-ehlorobenzoyl)-4-chlorophenyl]-5-(chloromethyl)-lH-1,2,4-tria~ole-3-carboxylic acid (crystals containing an equimolar amount of methanol; see German 'Offelllegungs-schrift' No. 2,1S~,527, page 32) in 1400 ml of methanol, and the whole is refluxed ior 18 hours. The reaction mixture is then concentrated in vacuo; water is added to the residue and extraction is performed twice with methylene chloride. The org~nic phase is washed once with saturated potassi~m bicarbonate solution, twice with water : , ., :~ ,:.

~074313 and once with saturated sodium ch1oride solution; it is subsequently dried over sodium sulphate and concentrated in vacuo. The residue is recrystallised from 1 litre of methanol. After drying there is obtained 1-[2-(o-S chlorobenzoyl)-4-chlorophenyl]-5-(chloromethyl)-lH-1,2,4-triazole-3-carboxylic acid methyl ester, m.p. 130-132.

b) A solution of 106.2 g (0.250 mole) of 1-[2-(o-chloro-benzoyl)-4-chlorophenyl]-5-(chloromethyl)-lH-1,2,4-triazole-3-carboxylic acid methyl ester and 56.2 g (0.375 mole) of sodium iodide in 2200 ml of acetone is refluxed for 40 minutes. The reaction mixture is thereupon concentrated in vacuo. Water is added to the residue, and extraction is performed twice with methylene chloride.
The organic phase is washed twice with diluted aqueous sodium bisulphite solution and twice with saturated sodium chlarlde solution; it is dried over sodium sulphate and concentrated in vacuo. The residue is dissolved in the minimum amount of methylene chloride, and 400 ml of ether is slowly added with stirring, wher~upon the reaction product crystallises out After filtration with suction and drying in vacuum, there is obtained 1-12-(o-chloro-benzoyl)-4-chlorophenyl~-5-(iodomethyl)-1~1-1,2,4-tri~zole-3-carboxylic acid methyl ester, m.p. 125-128.

. . ..
.

Example 14 A mixture of 12.90 g (0.025 mole) of 1-12-(o-chloro-benzoyl)-4-chlorophenyl]-5-(iodomethyl)-lH-1,2,4-triazole-3-carboxylic acid methyl ester lsee Example 13 b)l and 11 ml of 33~/0 ethanolic dimethylamine solution S in 250 ml of methanol is stirred ~or 7 hours at room temperature. The reaction solution is thereupon concentrated in vacuo; water is added to the residue and the whole is extracted twice with methylene chloride. The organic phase is washed twice with water and once with saturated sodium chloride solution; it is dried over sodium sulphate and concentrated in vacuo to dryness. The amorphous residue is dissolved in 130 ml of ether; the solution is allowed to stand and ~he reaction product then crystallises out. It is ~iltered of~ with suction and washed with ether. A~ter drying there is obtained 1-12-(o-chloro-- benzoyl)-4-chlorophenyl)-5-l(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxylic acid methyl es-er, m.p.
131-134.

, , . ... - .

.. . . . . ; ;- . .... ... . .: ...

1~743~3 Example 15 28.5 g (0.06 mole) o~ 1-[2-(o-chlorobenzoyl)-4-chlorophenyl]-5-(morpholinomethyl)-1~-1,2,4-triazole-3-carbGxylic acid methyl ester is covered over with 730 ml of methanol and 290 ml of concentrated aqueous S ammonia solution. The mixture is heated, with stirring, ~or 4 hours at 40, during which time the starting material slowly goes into solution. The reaction solution is then allowed to stand for 18 hours at room temperature and is subsequently concentrated in vacuo. Water is added to the residue and extraction is periormed twice with ethyl acetate. The combined organic extracts are shaken with ice and and sufficient 2N hydrochloric acid ~olution to bring the p~ value to 3. The hydrochloride, obtained in crystalline ~orm, is washed with water and et~yl acetate. The acid aqueous layer is separated from the filtrate and combined with the suction-filter residue.
There is then added 5N sodiu~ hydroxide solu~ion until the pH-value has reached 9, and the precipitated ~ase is dissolved in methylene chloride. The methylene chloride solution is washed once with water and twice with saturated sodium chloride solution; it is dried over sodium sulph~te and concentrated in vacuo. The residue is dissolved in a , . . -. ., -. - , ~ . . :,~ . -. . : , :
,..... .. .
., ...... ~ . .. , , ~- ` -: -10743~ 3 mixture of methylene chloride and isopropanol; the methylene chloride is evaporated off at normal pressure, and cooling to room temperature is effected. The crystalline reaction product is filtered off with suction and washed with isopropanol and ether. After drying in vacuum, the resulting 1-12-(o-chlorobenæoyl)-4-chlorophenyl]-5-(morpholinomethyl)-lH-1,2,4-triazole-3-car~oxamide melts at 165-167.

The following are obtained in an analogous manner:

from 27.6 g (0.06 mole) of 1-12-(o-chlorobenzoyl)-4-chlorophenyl]-5-[(1-pyrrolidinyl)-methyl]-lH-1,2,4-triazole-3-carboxylic acid methyl ester there is obtained 1-[2-(o-chlorobenzoyl)-4-chlorophenyl]-5-1(1-pyrrolidinyl)-methyl]-lH-1,2,4-triazole-3-carboxamide;

~rom 28.4 g (0.06 mole) of 1-[2-(o-chlorobenzoyl)-4-chlorophenyl]-5-(piperidinomethyl)-lH-1,2,4-triazole-3-carboxylic acid methyl ester there is obtained 1-[2-(o-chlorobenzoyl)-4-chlorophenyl]-5-(piperidinomethyl)-lH-. 1,2,4-triazole-3-carboxamide; and A 20 from 27.7 g (0.06 mole) of 1-l2-1chlorobenzoyl)-4-chlorophenyl]-5-[(diethylarnino)-methyl]-lH-1,2,4~triazole-3-carboxylic acid methyl ester there is obtained l-L2-(o-chloro~enzoyl)-4-chlorophenyL]-5-[(diethylamino)-methy~ 2~4-triazole-3 carboxamide.

, . :. , ' . .' :: ., .'. , , ., . :

Example 16 With the use of a solution of 20 g (about 0.65 mole) o methylamine in 120 ml of methanol, inste~d of the ammonia solution, there is obtained, with the procedure otherwise being analogous to that described in Example 15, N-methyl-1-12-(o-chlorobenzoyl)-4-chlorophenyl]-5-~morpholinomethyl)-lH-1,2,4-triazole-3-carboxamide.

There are obtained likewise analogously, starting with the given amounts of the further three methyl esters mentioned in Example 15:

N-methyl-1-[2-~o-chlorobenzoyl)-4-chlorophenyl]-5-l(l-pyrrolidinyl)-methyl] l~-1,2,4-triazole-3-carboxamide;

N-methyl-1-l2-(o-chlorobenzoyl)-4-chlorophenyl]-5-(piperidinomethyl)-lH-1,2,4-~riazole-3-carboxamide; and N-methyl-1-(2-(o-chlorobenzoyl)-4-chlorophenyl]-5-l(dietnyl-amino)-methyll-lH-1,2,4-triazole-3-carboxamide.

~ .: ,: ,. . .
. . .
- , :

: , . : -1~1174313 Example 17 8.66 g (0.020 mole) of 1-[2-(o-chlorobenzoyl)-4-chloro-phenyl)-5-l(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxylic acid methyl ester is co~7ered over with 400 ml of methanol and 80 ml of concentrated aqueous S ammonia solution. The reaction solution is stirred for 16 hours at room temperature, and thereupon concentrated in vacuo to dryness. Water is added to the residue and extraction is performed twice with methylene chloride.
The organic phase is washed twice with ice-cold lN
sodium hydroYide solution and is then extracted twice with 2N hydrochloric acid solution. To the aqueous acidified solutions there are added ice and sufficient SN sodium hydroxide solution to bring the pH-value to 10.
The precipitated base is taken up in methylene chloride.
The or~anic phase is washed twice with water and once with saturated sodium chloride solution; it is dried over sodium sulphate and concentrated by evaporation to dryness.
The amorphous residue is triturated with ether, whereupon the reaction product precipitates in crystalline form. It is filtered off with suction and washed with ether. After drying, there is obtained l-[2-(o-chlorobenzoyl)-4-chloro-phenyl]-5-~(dimethylamino)-methyl]-lH-l~2)4-triazole-3-.. . . ... ,, - - -, ,~ :, . .: .. ....
.. : :-. ... ;. .
- , ,.. ;., : ;.. . - . ~ ,, . . . -.
:. . : .: ,. : . .

carboxamide, m.p. 177-180.

There is obtained in an analogous manner, with the use o~ 6.5 g (0.21 mole) of methylamine in 40 ml of me~hanol instead of the concentrated aqueous ammonia S solution, N-methyl-1-[2-(o-chlorobenzoyl)-4-chlorophenyl]-5-[(dimethylamino)-methyl~-lH-1,2,4-triazole-3-carboxamide.

- ~0 -- - ,. , : -,~ : , , -, : , -, .
. ,, . , - :, Example 18 A mixture of 8.0 g (0.015 mole) of 1-[2-(o-chloro-benzoyl)-4-chlorophenyl]-5-(iodomethyl)-lH-1,2,4-triazole-3-carboxylic acid methyl ester lsee Example 13 b)]
and 3.3 ml of l-methyl-piperazine in 160 ml of methanol is stirred for 16 hours at 40. The reaction solution is then concentrated in vacuo; water is added to the residue and extraction is performed twice w;th methylene chloride. The organic phase is washed ~ice with ice water, and extraction is then performed twice with 2N hydrochloric acid solution. To the aqueous acidified extracts there are added ice and sufficient 5N sodium hydroxide solution to bring the pH-value to 10. The base that has precipitated is taken up in ether. The organic phase is washed twice , wi.th saturated sodium chloride solution; it is afterwards dried over 80dium sulphate and concentrated in vacuo to dryness. There is obtained 1-[2-(o-chlorobenzoyl)-4-chlorophenyl]-5-[(4-methyl-1-piperazinyl)-methyl]-lH-1,2,4-triazole-3-carboxylic acid methyl ester as solidiied foam.
The a~ove crude product is covered over with ~80 ml of methanol and 56 ml o~ concentrated aqueous ammonia solution. The reaction solution is stirred for about 15 - 8~ -: - , : . : - , . ,.:

10743~3 hours at room temperature and is thereupon concentrated in vaeuo. Water is added to the residue and extraction is performed twice with methylene chloride. The organic extracts are washed twice with ice-cold lN sodium hydroxide solution, twice with water and once with saturated sodium chloride solution; they are dried over sodium sulphate and concentrated in vacuo to dryness.
The residue is recrystallised from isopropanol. After drying, there is obtained 1-[2-(o-ehlorobenzoyl)-4-ehlorophenyl]-5 L (4-methyl-1-piperazinyl)-methyl]-lH-1,2,4-triazole-3-carboxamide, m.p. 167-169.

.. ... .

,. ~ -:. , - ; -: ,. . . :, ., ., . - . .; ., Example 19 2.50 ml (corresponding to 0.0067 mole of chromium trioxide) of an oxidation solution according to Jones (preparation of 250 ml by dissolving of 66.8 g of chromium trioxide in 57.5 ml of concentrated sulphuric S acid and making up with water to 250 ml) is added dropwise at room temperature, with stirring, to a solution of 4.22 g (0.01 mole) of 1-[2-(~-hydroxybenzyl)-4-chlorophenyl]-5-[(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxamide-hydrochloride in 800 ml of acetone.
The reaction mixture, gradually assuming a green colour, is stirred for 18 hours at room temperature, and then concentrated in vacuo to 100 ml. Ice and saturated sodium carbonate solution are added until the pH-value has reached 10, and extraction is performed twice with ethyl acetate.
The organic phase is washed twice with water and once with saturated sodi~ chloride solution and dried over magnesium sulphate. The drying agent is filtered off, and there is added to the filtrate ethereal hydrogen chloride solution until the pH-value has reached 3. The hydrochloride, precipitating in crystalline form, is filtered off with suction and washed with ethyl acetate and ether. After drying in vacuo, there is obtained l-(2-benzoyl-4-chloro-,~ ,.
... . ..
. . -, .:
.
,; , ... .
.

phenyl)-5-[(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxamide-hydrochloride, m.p. 250 (with decomposition).
The starting material is produced as follows:

a) 0.57 g (0.015 mole) of sodium borohydride is added S all at once at 0, with stirring, to the solution of 5.6 g (0.015 mole) of 1-(2-benzoyl-4-chlorophenyl)-5-(chloromethyl)-lH-1,2,4-triazole-3-carboxamide Isee Example la)] in 250 ml of tetrahydrofuran and 25 ml of methanol, and the whole is subsequently stirred for a further hour at room temperature. There is then slowly added dropwise, with ice-water cooling, lN hydrochloric acid solution until ~he pH-value of the reaction mixture has reached 4. The mixture obtained is concentrated in vacuo to dry~ess. Water is added to the residue, and extraction is perormed t~ice with ethyl acetate. The organic phase is wash~d once with saturated potassium bicarbonate solution, twice with water and once with saturated sodium chloride solution; it is dried over sodium sulphate and concentrated in vacuo. There is obtained amorphous 1-¦2-(~-hydroxybenzyl)-4-chlorophenyl~-5-(chloromethyl)-1~-1,2,4-triazole-3-carboxamide, which can be used directly in the next stage. On the silica gel plate, the compound has an Rf value of 0.61 in the system ethyl acetate/methanol (95:5)-. . , , ~ , , : , - . ... : : . ..

b) 6.8 ml of 33~/~ ethanolic dimethylamine solution is added to a solution of 5.6 g (about 0.015 mole) of 1-[2-(a-hydroxybenzyl)-4-chlorophenyl]-5-(chloromethyl)-lH-1,2,4-triazole-3-carboxamide and 0.225 g of sodium iodide in 80 ml of methanol, and the whole is refluxed for 5 hours with stirring. The reaction mixture is thereupon concentrated in vacuo. Water and saturated sodium carbonate solution are added to the residue until the pH-value has reached 10, and extraction is performed twice with ethyl acetate. The organic phase is washed with water, and is then extracted three times with lN
hydrochloric acid solution. Sodium carbonate is added to the aqueous acidified extracts until the pH-value of 10 is obtained. The base that has precipitated is taken up in ether; the ether solution is washed twice with water and once with saturated sodium chloride solution;
it is dried over sodium sulphate and concentrated in vacuo to yield amorphous l-12-(a-hydroxybenzyl)-4-chloro-phenyl]-5-~(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxamide. This is converted as follows into thecrystalline hydrochloride: the crude base ls dissolved in ethyl acetate, and ethereal hydrogen chloride solution . , . . ;. .- ~
.. - . .
t . ..

- ; ~ .,...... ~ . -is added until the pH-value is 4. The precipitated hydrochloride is filtered off with suction and washed with ethyl acetate and ether. After drying in vacuum, there is obtained l-l2-(a-hydroxybenzyl)-4-chlorophenyl]-5-[(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxamide-hydrochloride, m.p. 15~-157 (with decomposition).

. , : '' '' '-` :,' ' ' '` " '`;
.' ' . ` ' ' ' ', . ' : ' ' "
- . '" ,-.~, ' ', ', _ ' ', Example 20 The crude [l-l2-(a-hydroxybenzyl)-4-chlorophenyl]-5-I(dimethylamino)-methyl]-lH-1,2,4-triazol-3-yl]-methyl]-acetate (about 0.028 mole), obtained according to b) lsee below], is dissolved in 1500 ml of acetone, and there is then added dropwise to the solution at room temperature in the course of 30 minutes, with stirring, 7.20 ml (corresponding to 0.019 mole of chromium trioxide) of an oxidation solution according to Jones which is prepared by dissolving 66.8 g of chromium trioxide in 57.5 ml of concentrated sulphuric acid and making up with water to 250 ml. The colour of the reaction mixture changes from the initial yellow via reddish brown to a deep dark green.
After completion of the dropwise addition, the reaction mixture is stirred for one hour at room temperature, and is thereupon concentrated in vacuo at 30 to the extent of 50%.
There are then added ice and saturated potassium bicarbonate solution until the pH-value reaches 8, and extraction is perormed twice with ethyl acetate. The combined organic phases are extracted twice with 2N hydrochloric acid solution. There are added to the aqueous ac~dified extracts ice and sufficient potassium carbonate to bring the pH-value to 8. The precipitated base is ta~en up in ethyl ..... . ~ , .. . .

1~74313 acetate. The organic phase is washed twice with water and once with saturated sodium chloride solution; it is dried over sodium sulphate and concentrated in vacuo to dryness. There is obtained crude [11-(2-benzoyl-4-chlorophenyl)-5-l(dimethylamino)-methyl]-lH-1,2,4-triazol-3-yl~-methyl]-acetate in the form of a slightly yellow oil.

A specimen of the crude product is dissolved in ether, and ethereal hydrogen chloride solution is added until the pH-value is 3. The hydrochloride, obtained in crystalline form, is filtered off with suction and, after drying, has a melting point of 166-170.
The starting material is produced as follows:

a) ~.1 g (0.24 mole) o~ sodium borohydride is added portionwise at room temperature, with stirring, to a solution of 16.0 g (0.040 mole) of 1-(2-benzoyl-4-chlorophenyl)-5-l(dimethylamino)-methyl]-lH-1,2~4-triazole-3-carboxylic acid methyl ester lsee ~xample 2]
in 320 ml of tetrahydrofuran and 320 ml of methanol. The temperature of the reaction solution rises during t'ne addition to 40. The reaction mixture is subsequently heated for one hour at 50; 100 ml of ice water is then , - - . . . ~ . .. ;. . :
r,::
:' '' ' ' ' ,''":' ,'.': " ' .1.' . . .' ~' . , :
: .'. '.-' ' ''.. '' . :' ' : ' ' added, and the bulk of the tetrahydrofuran and of the methanol is evaporated off in vacuo. The aqueous residue is extracted twice with ethyl acetate. The organic phase is washed once with lN sodium hydroxide solution, and is then extracted three times with 2N hydrochloric acid solution. Sodium carbonate is added to the a~ueous acidified extracts until the pH-value reaches 10. The precipitated base is dissolved in ethyl acetate; the solution is washed twice with water and once with saturated sodium chloride solution; it is dried over sodium sulphate and concentrated in vacuo. The residue is triturated with ether and hexane, whereupon the reaction product precipitates in crystalline form. After filtration with 8uction and drying in vacuum, there is obtained 1-[2-(~-hydroxybenzyl)-4-chlorophenyl]-5-[(dimethylamino)-methyll-lH-1,2,4-~riazole-3-methanol, m.p. 121-123.

b) A solution of 3.0 ml (0.0318 mole) of acetic anhydride in 5 ml o methylene chloride is addcd dropwise at 0 within 10 minutes to the solution of 11.18 g (0.030 mole) of 1-12-(a-hydroxybenzyl)-4-chlorophenyl]-5-[(dimethyl-amino)-methyl]-lH-l~2~4-triazole-3-methanol in 80 ml of methylene chloride and 10 ml of pyridine, and the whole is stirred for 20 hours at room temperature. There is - . ,~ '~ '' '' '. -- ,, , ; .. :- , .~
- , ., -, ...

1~743~3 then added a further 1.1 ml (0.012 mole) of acetic anhydride, and stirring is maintained for 4 hours at room temperature. The reaction mixture is concentrated in vacuo, and the residue is concentrated to dryness S twice with toluene. The amorphous residue is dissolved in ethyl acetate, and the organic phase is washed twice with water and once with saturated sodium chloride solution. After drying over sodium sulphate and concentration in vacuo, there is obtained amorphous ll-[2-(~-hydroxybenzyl)-4-chlorophenyl]-5-l(dimethylamino)-methyl]-lH-1,2,4-triazol-3-yl]-methyl]-acetate, which can be used directly in the next step. To determine characteristic properties, a specimen of the crude product is dissolved in acetone, and a saturated solution of oxalic acid in acetone is added until the pH-value of 3 is reached. The oxalate, which has crystallised out, is filtered off with suction, and recrystallised from hot acetone. After drying, the oxalate melts at 185-186 with decomposition.

Example 21 60 ml of lN sodium hydroxide solution (0.060 mole) is added at room temperature, with stirring, to a solution of ,.~.. . .... . .. ..

lV74313 g.26 g (about 0.020 mole) of crude [~1-(2-benzoyl-4-chlorophenyl)-5-[(dimethylamino)-methyl]-lH-1,2,4-triazol-3-yl]-methyl]-acetate (see Example 20) in 250 ml of methanol and 115 ml of water. The temperature of the reaction solution rises to 33. The reaction mixture is stirred for one hour at room temperature, and is subsequently concentrated in vacuo. Water is added to the residue, and extraction is performed t-~!ice with ethyl acetate. The combined organic phases are extracted three times with 2N hydrochloric acid. There are added to the aqueous acidified extracts ice and sufficient sodium carbonate to bring the p~-value to 10.
The precipitated base is taken up in ethyl acetate. The organic phase is washed twice with water and once with saturated sodium chloride solution; it is dried over sodi-~ sulphate and concentrated in vacuo. There is obtained crude 1-(2-ben~oyl-4-chlorophenyl)-5-l(dime~hylamino)-methyl]-lH-1,2,4-triazole-3-methanol as solidified foam.

A specimen of the crude product is dissolved in etller, and ethereal hydrogen chloride solution is added until the pH-value is 3. The hydrochloride, obtained in crystalline form, is filtered off with suction and, after drying, melts at 198-200 with decomposition.

, , , - . .. ..

. .

10743~3 Example 22 2.63 ml (corresponding to 0.007 mole of chromium trioxide) of the oxidation solution according to Jones [see Example 20] is added dropwise at 0 to 5, with stirring, to a solution of 3.0 g (0.008 mole) of crude 1-(2-benzoyl-4-chlorophenyl)-5-l(dimethylamino)-methyl~-lH-1,2,4-triazole-3-methanol (see Example 21) in 670 ml of acetone.
The reaction mixture, which assumes after some ~ime a deep green colour, is stirred for 2 hours at room temperature, and afterwards concentrated in vacuo to the extent of 50%.
lQ There are then added ice and saturated sodium carbonate solution until the pH-value of 9 is obtained, and extraction is performed twice with ethyl acetate. The combined organic phases are washed twice with water and once with saturated sodium chloride solution; they are dried over sodium sulphate and concentrated in vacuo to dryness. The residue is dissolved in ethyl acetate/isopropanol (4:1), and the solution is chromatographed on a column of 200 g of silica gel. The eluant used is ethyl aceta~e/
isopropanol (4:1). The fractions which contain the desired aldehyde are combined and concentrated by evaporation.
There is obtained crude 1-(2-benzoyl-4-chlorophenyl)-5-I(dimethylamino)-methyll-lH-l~2~4-triazole-3-carboxaldehyde :.

,:,.: ~ ~ . : ., .. :
, ~ : , , . .. : , .:

- : : : ; - :. .: -.. ... . . ..

as solidified foam.

A specimen of the aldehyde is dissolved in acetone, and a saturated solution of oxalic acid in acetone is added until the pH-value is 3. The oxalate precipitates S in crystalline form. It is filtered off with suction, washed well with acetone and ether and dried in vacuo;
m.p. 178-181 with foaming.

Example 23 5.1 ml (corresponding to 0.0136 mole of chromium trioxide) of the oxidation solution according to Jones (see Example 20) is added dropwise at 0, with stirring, to a solution of 3.79 g (0.001 mole) of 1-12-(a-hydroxy-benzyl)-4-chlorophenyl~-5-l(dimethylamino)-methyl]-3-methanol in 740 ml of acetone, and the whole, after completio~ of the dropwise addition, is stirred for a further 30 minutes at room temperature. The green reaction mixture is thereupon concentrated in vacuo to half its amount; ice water and saturated sodium carbonate solution are added until the p~-value reaches 9, and extraction is performed twice with ethyl acetate. The combined organic phases are washed twice with water and once with saturated sodium chloride solution; they are dried over sodium sulphate : ~ . ~ . .. . .
, i . . . . . . .. . . . .
. .- . ~ . , -.
.

and concentrated in vacuo. The amorphous residue is dissolved in ethyl acetate/isopropanol (4:1), and the solution is chromatographed on a column of 250 g of silica gel. The eluant used is ethyl acetate/isopropanol (4:1). The fractions which contain the desired aldehyde are combined and concentrated by evaporation. The residue is dissolved in acetone, and a saturated solution of oxalic acid in acetone is added until the pH-value is 3.
The oxalate, obtained in crystalline form, is filtered off with suction, and washed with acetone and ether.
After drying, there is obtained 1-(2-benzoyl-4-chlorophenyl)-5-[(dimethylamino)-methyll-lH-1,2,4-triazole-3-carboxaldehyde-oxalate, m.p. 178-181 with foaming.

Example 24 - ~ solut~on of 0.78 ml (0.01 mole) of methanesulphonic acid chloride in 8 ~1 of anhydrous methylene chloride is added dropwise at 0, with stirring, to the solution of 2.0 g (0.005 mole) of crude 1-(2-benzoyl-4-chlorophenyl)-5-~(dimethylamino)-methyll-1~-1,2,4-triazole-3-methanol in 66 ml of anhydrous methylene chloride and 1.33 ml of triethylamine, and the whole is stirred, without further cooling, for one hour. Ice water and 120 ml of methylene .

.- . . . , -~ . . ~ . ..
. ~ . ,: . - , 10743'13 chloride are added to the reaction mixture; the aqueous phase is separated, and the organic phase is washed twice with ice-cold potassium bicarbonate solution and twice eh/0~ c with saturated sodiumlsolution. After drying over magnesium sulphate and removal of the solvent by evaporation in vacuo, there remains the crude methane sulphonic acid ester of the starting material.

The crude methanesulphonic acid ester obtained above i8 dissolved in a mixture of 4.6 ml (0.03 mole) of 30%
ethanolic dimethylamine solution and 60 ml of methanol, and the solution is allowed to stand for 16 hours. The reaction mixture is then evaporated in vacuo to dryness;
there are added to the residue ice water and su~ficient saturated sodium carbonate solution to bring the pH-value to 10; and extraction is performed three times with ethyl flce~ate. The organic phase is washed once with water, and iB thereupon extracted three times with 2N hydrochloric acid. Sodium carbonate is added to the acidified aqueous extracts until the pH-value is 10, and extraction is then performed twice with ethyl acetate. The combined ethyl acetate solutions are washed twice with water and once with saturated sodium chloride solution; they are dried over magnesium sulphate and filtered. There is added to the - ~5 -~ '~ ' , , . ~ . .

filtrate sufficient ethereal hydrogen chloride solution to bring the pH-value to 3. The product, precipitating in crystalline form, is filtered off with suction, and thoroughly washed with ethyl acetate and ether. After S drying in vacuo, there is obtained 1-(2-benzoyl-4-chlorophenyl)-3,5-bis-l(dimethylamino)-methyl~-lH-1,2,4-triazole-dihydrochloride, m.p. 90 (with gradual decomposition).

~ ,. . ...... ... .. . .

- .. .

1~74313 Example 25 A mixture of 4.18 g (0.01 mole) of 1-[2-(o-chloro-benzoyl)-4-chlorophenyl]-5-~(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxamide and 2.86 g (0.015 mole) of p-toluenesulphonic acid chloride in 2.42 ml of pyridine and 24 ml of N,N-dimethylformamide is stirred for 2 hours at room temperature. The initially yellow colour of the reaction mixture changes during this time to green and then to red-brown. The reaction solution is poured into ice water, and extraction is performed twice with ether. The organic phase is washed three times with water and once with saturated sodium chloride solution;
it is dried over sodium sulphate and concentrated in vacuo to dryness. The residue is crystallised from isopropanol.
After filtration with suction followed by drying, there i8 obt~ined 1-12-(o-chlorobenzoyl)-4-chIorophenyl3-5-l(dimethylamin~)-methyll-lH-1,2,4-triazole-3-carbonitrile, m.p. 117-119.
There is obtained analogously, from 3.84 g (0.01 mole) of 1-(2-benzoyl-4-chlorophenyl)-5-l(dimethylamino)-methyl~-lH-l~2~4-triazole-3-carboxamide~
amorphous l-(2-benzoyl-4-chlorophenyl)-5-~(dimethylamino)-methyll-lH-1,2,4-triazole-3-carbonitrile. An addition is .

.,, , : . . .

1~74313 made to this compound in etheral solution of a solution o hydrogen chloride in ether, whereupon the crystalline h~drochloride precipitates; it is filtered with suction and washed with ether and hexane. After drying, the resulting 1-(2-benzoyl-4-chlorophenyl)-5-l(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carbonitrile-hydrochloride melts at 216-219 with decomposition.

Example 26 150 ml of isopropanol is saturated at 0 with ammonia gas. To this solution there are added at 0, with stirring, 2.45 g (0.05 mole) of sodium cyanide and, after 5 minutes, a solution of 3.69 g (0.01 mole) of crude 1-(2-benzoyl-4-chlorophenyl)-5-l(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxaldehyde in 30 ml of isopropanol. There are then added at 0, at intervals of 10 minutes, 2 portions each of 8.70 g (0.10 mole) of manganese dioxide, and the reaction mixture is stirred for 4 hours at 0.
The reaction mixture is thereupon diluted with 250 ml of methylene chloride, and the whole is filtered through diatomaceous earth. The clear filtrate is concentrated in vacuo to dryness. The residue is dissolved in ethyl acetate/methanol (4:1), and the solution is chromatographed t ' ' ' 1~74313 on a column of 300 g of silica gel. The eluant used is cthyl acetate/methanol (4:1). The fractions which contain the desired product are combined and concentrated by evaporation. The amorphous residue is dissolved in 50 ml of ethyl acetate, and ethereal hydrogen chloride solution is added until an acid reaction to Congo red is indicated. The hydrochloride, obtained in crystalline ; form, is filtered off with suction and washed with ethyl acetate and ether. After drying, the resulting 1-(2-benzoyl-4-chlorophenyl)-S-[(dimethylamino)-methyl]-; lH-1,2,4-triazole-3-carboxamide-hydrochloride melts at 250 with decomposition.

The aldehyde required as starting material can be produced according to Example 22 or 23.

_ 99 _ .;

, .,~ . . . .

1~743~3 Example 27 40 ml of lN sodium hydroxide solution is added to the solution of 5.37 g (0.01 mole) of crude [2-(dimethyl-amino)-acetamido-[2-(o-chlorobenzoyl)-4-chlorophenylazo]-malonic acid diethyl ester in 60 ml of methanol, and the reaction mixture is heated, with stirring, for 3 hours at 50. The methanol is thereupon evaporated off in vacuo, the residue is diluted with ~0 ml of water and 1 g of active charcoal is added. After filtration through purified diatomaceous earth, there is added to the clear filtrate 2N hydrochloric acid solution until the pH-value is 7, and washing with methylene chloride is performed. The aqueous phase is then concentrated to dryness in vacuo, and the residue, to effect complete drying, i8 concentrated twice with methanol/toluene (1:1) in vacuo at 40. The residue is sub~equently boiled out with methanol. The undissolved inorganic salts are ~eparated off by filtration through purified diatomaceous earth, and the clear filtrate is concentrated by evaporation to dryness. The residue consists of pure 1-[2-(o-chloro-benzoyl)-4-chlorophenyll-5-[(dimethylamino)-methyl]-lH-1,2,4-triazole-3-carboxylic acid, which optionally can be used directly for the next step, the convergion into ,', ' ": ,, ' ' , , ' '; ' ~: " :,' ' . : : .
' ' " , ~ ~ ' 1~74313 the methyl ester serving for its part, e.g., as r 8tarting material for Example 15.
For conversion into the hydrochloride, a saturated solution of hydrogen chlorlde in ether is added to a specimen of the carboxylic acid in ethanol until the pH-value of the mixture, after the addition of water, is 3. After the addition of ethyl acetate, the salt crystallises out. It is filtered off with æuction and washed with ethyl acetate and hexane. After drying, the resulting 1-[2-(o-chlorobenzoyl)-4-chlorophenyl]-5-(dimethylamino-methyl)-lH-l,2,4-triazole-3-carboxylic acid-hydrochloride melts at 220 with decomposition.
For conversion into the methyl ester already mentioned, 10 ml of a 6N solution of hydrogen chloride in methanol is added to a solution of 2.08 g (0.005 mole) of crude 1-[2-(o-chlorobenzoyl)-4-chlorophenyl]-5-(dimethylamino-methyl)-lH-1,2,4-triazole-3-carboxylic acid in 30 ml of methanol, and the whole is refluxed for 16 hours. The reaction mixture is thereupon concentrated in vacuo.
20 Water is added to the residue, and extraction is performed twice with methylene chloride. The organic phase is washed twice with ice-cold lN sodium bicarbonate solution and twice with saturated sodium chloride solution; it is dried over . .

- , . .:..... . . .
. - . . .

lQ74313 sodium sulphate and concentrated in vacuo. The residue crystallises out on trituration with ether. After filtration with suction and drying in vacuo, there is obtained pure 1-12-(o-chlorobenzoyl)-4-chlorophenyl]-5-(dimethylamino-methyl)-lH-1,2,4-triazole-3-carboxylic acid methyl ester, m.p. 133-135.

The starting material for the first step (ring closure) is produced as follows:
a) A solution of 5.02 g (0.02 mole) of (2-chloroacetamido)-malonic acid diethyl e~ter [see Ajay Kumar Bose, J.Indian Chem. Soc. 31, 108-110 (1954)] and 4.50 g (().03 mole) of sodium iodide in 100 ml of acetone is refluxed for 30 minutes. The reaction mixture is thereupon concentrated in vacuo. Water is added to the residue, and extraction lS i8 performed twice with methylene chloride. The organic pha8e i8 washed once with diluted aqueou~ sodium bisulphite ~olution and twice with saturated sodium chloride solution;
it is dried over sodium sulphate and concentrated in vacuo.
The residue i8 recrystallised from methylene chloride/
hexane. After filtration with suction and drying in vacuo, there is obtained (2-iodoacetamido)-malonic acid diethyl ester, m.p. 95-97.
b) A mixture of 5.16 g (0.015 mole) of (2-iodoacetamido)-I . ' .

: . . . - . , ... . ..

malonic acid diethyl ester and 8.0 ml (0.045 mole) of 33% ethanolic dimethylamine solution in 50 ml of ethanol is stirred for 16 hours at room temperature.
The reaction solution is thereupon concentrated in vacuo; water is added to the residue and extraction is performed twice with ether. The organic phase is washed twice with ice water and once with saturated sodium chloride solution; it is dried over sodium sulphate and concentrated in vacuo. The residue, a viscous oil, is practically pure 12-(dimethylamino)-acetamido]-malonic acid diethyl ester, and is used directly for the next step.
c) A solution of 4.53 g (0.017 mole) of 2-amino-2',5-dichloro-benzophenone lsee ~.H. Sternbach et al., J.Org.
Chem. 26, 4448 (1961)] in 21 ml of glacial acetic acid/
conc. hydrochloric acid (4:1) is diazotised at room temperature, with stirring, with 3.4 ml (0.014 mole) of 5-molar aqueous sodium nitrite solution. The diazonium salt solution obtained is cooled to 10j 9 g of ice is added thereto and there is then quickly added dropwise a solution of 4.43 g (0.017 mole) of crude 12-(dimethyl-amino)-acetamido]-malonic acid diethyl ester in 44 ml of acetone. There is su~sequently added dropwise at 5-10, within 15 minutes, a saturated aqueous potassium car~onate solution until the pH-value is 6. Stirring is maintained for a further hour at room temperature, and 150 ml of ether is then added. The ether layer is separated, and washed twice with ice water and once with saturated sodium chloride solution; it is dried over sodium sulphate and concentrated in vacuo. The residue, a yellow-brown oil, consists of practically pure [2-(dimethylamino) acetam~do~-12-(o-chlorobenzoyl)-4-chlorophenylazo]-malonic acid diethyl ester. The compound shows on silica gel thin-layer plates an Rf-value of 0.36 in the system toluene/ethyl acetate (1:1).

:

, ~ .

Example 28 A solution of 5.37 g (0.01 mole) of crude [2-(dimethyl-~mino)-acetamidol-[2-(o-chlorobenzoyl)-4-chloro-phenylazo]-malonic acid diethyl ester lsee Example 27 a) to c)] and 50 ml of conc. aqueous ammonia solution in S 100 ml of methanol is stirred for 16 hours at room temperature. The reaction mixture is thereupon concentrated in vacuo. Water is added to the residue and extraction i8 performed twice with methylene chloride. The organic phase i8 extracted twice with ice-cold lN hydrochloric acid. To the acid aqueous extraction there is added 5N
sodium hydroxide solution until the pH-value has reached 11; and the formed dispersion of the reaction product is extracted twice with methylene chloride. The organic phase is washed twice with water and once with saturated 80dium chloride solution; it is dried over sodium sulphate and concentrated in vacuo to dryness. The residue crystallises out on trituration with ether. After filtration with suction and drying in vacuo, there is obtained, as a result of decarbethoxylation, ring closure and ammonolysis of the ester group remaining, performed in the same operation, 1-12-(o-chlorobenzoyl)-4-chlorophenyl]-5-l(dimethylamino)-methyl)-lH-1,2,4-triazole-3-carboxamide, m.p. 178-180~. - 105 -

Claims (23)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. Process for the production of new triazole derivatives of the formula I

(I) wherein R1 represents hydrogen, lower alkyl, hydroxymethyl, lower alkanoyloxy methyl, lower alkoxy methyl, formyl, carboxy, lower alkoxy carbonyl, cyano or a group of the partial formula Iaa (Iaa) in which X represents oxygen or two hydrogen atoms and R4 and R5 each independently represent hydrogen, lower alkyl having at most 3 carbon atoms, or together with the adjacent nitrogen atom, they represent morpholino, 1-pyrrolidinyl, or piperidino, R2 represents lower alkyl, R3 represents hydrogen or lower alkyl or together with the adjacent nitrogen atom they represent morpholino, 1-pyrrolidinyl or piperidino the rings A and B independently of each other are unsubstituted or substituted by halogen up to atomic number 35, trifluoromethyl, nitro, lower alkyl or lower alkoxy and their pharmaceutically acceptable addition salts, wherein a) a reactive ester of a compound of the general formula II

(II) selected from the group consisting of hydrohalic acid esters and sulfonic acid esters, wherein R1 has the meaning given under formula I, and the rings A and B are as hereinbefore defined, is reacted with a compound of the general formula III

(III) wherein R2 and R3 have the meanings given under formula I, or with an alkali metal derivative of such a compound in which R3 has a meaning other than hydrogen; or b) for the production of compounds of the general formula I
wherein R2 and R3 represent methyl, while R1 has the meaning given under formula I, a compound of the general formula IV

(IV) in which R1 has the meaning given under formula I, and the rings A and B are as hereinbefore defined, is reacted with formaldehyde and formic acid; or c) for the production of compounds of the general formula I
wherein R1 has the meaning given under formula I with the exception of hydroxymethyl, and R2 and R3 have the meanings given under formula I, a compound of the general formula V

(V) wherein R1, R2 and R3 have the meanings given under formula I, and the rings A and B are as hereinbefore defined, is oxidized; or d) for the production of compounds of the general formula I
wherein R1 represents carboxy or lower alkoxycarbonyl, while R2 and R3 have the meanings given under formula I, a basic medium is allowed to react with a compound of the general formula VI

(VI) in which R6 represents lower alkyl, R2 and R3 have the meanings given under formula I, and the rings A and B are as hereinbefore defined;
and, optionally, a compound I obtained by any one of the processes given under a) to d) is converted into pharmaceutically acceptable addition salt with an inorganic or organic acid; or, optionally, e) for the production of compounds of the general formula I
wherein R1 represents optionally mono- or disubstituted carbamoyl, while R2 and R3 have the meanings given under formula I, a carboxylic acid of the general formula Ie embraced by the general formula I

(Ie) in which R2 and R3 have the meanings given under formula I, and the rings A and B are as hereinbefore defined, or a reactive lower alkyl ester, sulfonic acid ester, p-nitrophenyl ester, hydrohalic acid ester, cyanomethylester or anhydride thereof, is reacted with a compound of the general formula VII

(VII) in which R4 and R5 each independently represent hydrogen or hydrocarbon radicals each having at most 10 carbon atoms, which, provided that they represent lower alkyl, can also be bound directly together, or they can be bound in the .beta.- or .gamma.-position by way of oxygen, sulphur, the imino group or a lower alkylimino radical, or with a reactive alkali metal derivative, N-tri-(lower alkyl)-silyl derivative or a N-chlorocarbonyl derivative of such a compound or with an alkyl isocyanate, alkylthiocyanate or sulfonic acid-monoalkyl-ester-monoamide; or f) for the production of compounds of the general formula I
wherein R1 is aminomethyl or mono- or disubstituted aminomethyl, while R2 and R3 have the meanings given under the general formula I, a reactive ester of a compound of the general formula If embraced by the general formula I:

(If) in which R2 and R3 have the meanings given under formula I, and the rings A and B are as hereinbefore defined, is reacted with a compound of the general formula VII given above, wherein R4 and R5 have the meanings given under this formula, or with an alkali metal derivative of such a compound; or g) for the production of a triazole derivative of the general formula I wherein R1 represents hydroxymethyl, while R2 and R3 have the meanings given under formula I, a compound of the general formula VIII

(VIII) in which Ac represents a lower alkanoyl radical, R2 and R3 have the meanings given under formula I, and the rings A and B are as hereinbefore defined, is solvolysed; or h) for the production of a triazole derivative of the general formula I wherein R1 represents formyl, while R2 and R3 have the meanings given under formula I, a compound of the general formula Ih (Ih) in which R2 and R3 have the meanings given under formula I, and the rings A and B are as hereinbefore defined, is oxidized; or i) for the production of a triazole derivative of the general formula I wherein R1 represents cyano, while R2 and R3 have the meanings given under formula I, a compound of the general formula Ii (Ii) in which R2 and R3 have the meanings given under formula I, and the rings A and B are as hereinbefore defined, is dehydrated; or j) for the production of triazole derivatives of the general formula I wherein R1 represents optionally mono- or disubstituted carbamoyl, while R2 and R3 have the meanings given under formula I, a compound of the general formula Ij embraced by the general formula Ij (Ij) in which R2 and R3 have the meanings given under formula I, and the rings A and B are as hereinbefore defined, is reacted with a compound of the general formula VII given above, wherein R4 and R5 have the meanings given under this formula, in the presence of an alkali metal cyanide and of a selective oxidizing agent;
and, optionally, a triazole derivative of the general formula I, obtained by any one process or by several successive processes according to e) to j) is converted into a pharmaceutically acceptable addition salt.
2. Process according to claim 1 in which R1 represents hydrogen, hydroxymethyl, lower alkanoyloxymethyl, formyl, carboxy, lower alkoxycarbonyl, cyano or a group of the partial formula Iaa (Iaa) and the rings A and B are independently of each other unsub-stituted or substituted by halogen up to atomic number 35, trifluoromethyl or nitro.
3. Process according to claim 1, in which R1 represents hydroxymethyl, lower alkanoyloxymethyl, formyl, carboxy, lower alkoxycarbonyl, cyano, or a group of the partial formula Iaa (Iaa) in which X represents oxygen or two hydrogen atoms, and R4 and R5 each independently represent hydrogen, lower alkyl having at most 3 carbon atoms, or together with the adjacent nitrogen atom they represent morpholino or alkyleneimino having 5 to 6 ring members, R2 and R3 represent lower alkyl having at most 2 carbon atoms, or together with the adjacent nitrogen atom, they represent morpholino or alkyleneimino having 5 to 6 ring members, ring A is substituted in the 4-position with respect to the tri-azole ring by halogen up to atomic number 35, or by nitro, and ring B is unsubstituted or substituted by halogen up to atomic number 35.
4. Process according to claim 1, comprising the preparation by one of the processes a), b), c), e), f) or j) of compounds of the general formula I, wherein R1 represents a group of the partial formula Iaa (Iaa) in which X represents oxygen or two hydrogen atoms, and R4 and R5 each independently represent hydrogen, lower alkyl having at most 3 carbon atoms, or together with the adjacent nitrogen atom they represent morpholino or alkyleneimino having 5 to 6 ring members, R2 and R3 represent lower alkyl having at most 2 carbon atoms, or together with the adjacent nitrogen atom, they represent morpholino or alkyleneimino having 5 to 6 ring members, ring A is substituted in the 4-position with respect to the triazole ring by halogen up to atomic number 35, or by nitro, and ring B is unsubstituted or substituted by halogen up to atomic number 35, and their pharmaceutically acceptable addition salts.
5. Process according to claim 1, wherein there are produced 1-(2-benzoyl-4-chloropheny1)-5- [(dimethylamino)-methyl] -1H-1,2,4-triazole-3-carboxylic acid, its methyl ester and its pharmaceutically acceptable addition salts by one of the processes a), b), c) or d).
6. Process according to claim 1, wherein there are produced 1-(2-benzoyl-4-chlorophenyl)-5- [(dimethylamino)-methyl] -1H-1,2,4-triazole-3-carboxamides and its pharmaceutically acceptable addition salts by one of the processes a), b), c), e) or j).
7. Process according to claim 1, wherein there are produced 1-[2-(o-chlorobenzoyl)-4-chlorophenyl]-5-[(dimethylamino)-methyl] -1H-1,2,4-triazole-3-carboxylic acid, its methyl ester and its pharmaceutically acceptable addition salts by one of the processes a), b), c) or d).
8. Process according to claim 1, wherein there are produced 1-(2-benzoyl-4-chlorophenyl)-5-(morpholinomethyl)-1H-1,2,4-triazole-3-carboxylic acid, its methyl ester and its pharmaceut-ically acceptable addition salts by one of the processes a), c), or d).
9. Process according to claim 1, wherein there are produced 1-[2-(o-chlorobenzoyl)-4-chlorophenyl]-5-(morpholinomethyl)-1H-1,2,4-triazole-3-carboxamides and its pharmaceutically acceptable addition salts by one of the processes a), c), e) or j).
10. Process according to claim 1, wherein there is produced N,N-dimethyl-1-[2-(o-fluorobenzoyl)-4-chlorophenyl]-5-[(dimethyl-amino)-methyl] -1H-1,2,4-triazole-3-carboxamide and its pharma-ceutically acceptable addition salts by one of the processes a), b), c), e) or j).
11. Process according to claim 1, wherein there is produced 1-[2-(o-chlorobenzoyl)-4-chlorophenyl] -3,5-bis-[(dimethylamino)-methyl) -1H-1,2,4-triazole and its pharmaceutically acceptable addition salts by one of the processes a), b), c) or f).
12. New triazole derivatives of the general formula I
given in claim 1, and their pharmaceutically acceptable addition salts, whenever produced by a process as claimed in claim 1.
13. New triazole derivatives of the general formula I
given in claim 2, and their pharmaceutically acceptable addition salts, whenever produced by a process as claimed in claim 2.
14. New triazole derivatives of the general formula I
given in claim 3, and their pharmaceutically acceptable addition salts, whenever produced by a process as claimed in claim 3.
15. New triazole derivatives of the general formula I
given in claim 4, and their pharmaceutically acceptable addition salts, whenever produced by a process as claimed in claim 4.
16. 1-(2-Benzoyl-4-chlorophenyl)-5- [(dimethylamino)-methyl)-1H-1,2,4-triazole-3-carboxylic acid, its methyl ester and its pharmaceutically acceptable addition salts, whenever produced by a process as claimed in claim 5.
17. 1-(2-Benzoyl-4-chlorophenyl)-5- [(dimethylamino)-methyl]-1H-1,2,4-triazole-3-carboxamides and its pharmaceutically acceptable addition salts, whenever produced by a process as claimed in claim 6.
18. 1-[2-(o-Chlorobenzoyl)-4-chlorophenyl]-5-[(dimethyl-amino)-methyl]-1H-1,2,4-triazole-3-carboxylic acid, its methyl ester and its pharmaceutically acceptable addition salts, when-ever produced by a process as claimed in claim 7.
19. 1-(2-Benzoy1-4-chloropheny1)-5-(morpholinomethyl)-1H-1,2,4-triazole-3-carboxylic acid, its methyl ester and its pharmaceutically acceptable addition salts, whenever produced by a process as claimed in claim 8.
20. 1-[2-(o-Chlorobenzoyl)-4-chlorophenyl]-5-(morpholino-methyl)-1H-1,2,4-triazole-3-carboxamides and its pharmaceutically acceptable addition salts, whenever produced by a process as claimed in claim 9.
21. N,N-dimethyl-1-[2-(o-fluorobenzoyl)-4-chlorophenyl]-5-[(dimethylamino)-methyl]-1H-1,2,4-triazole-3-carboxamide and its pharmaceutically acceptable addition salts, whenever produced by a process as claimed in claim 10.
22. 1-[2-(o-Chlorobenzoyl)-4-chlorophenyl)-3,5-bis-[(dimethylamino)-methyl]-1H-1,2,4-triazole and its pharma-ceutically acceptable addition salts, whenever produced by a process as claimed in claim 11.
23. Process according to claim 3 in which ring A is substituted in the 4-position with respect to the triazole ring by chlorine and ring B is unsubstituted or substituted by fluorine or chlorine in the ortho-position.
CA229,230A 1974-06-14 1975-06-12 Process for the production of new triazole derivatives Expired CA1074313A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH817574A CH601264A5 (en) 1974-06-14 1974-06-14

Publications (1)

Publication Number Publication Date
CA1074313A true CA1074313A (en) 1980-03-25

Family

ID=4336312

Family Applications (1)

Application Number Title Priority Date Filing Date
CA229,230A Expired CA1074313A (en) 1974-06-14 1975-06-12 Process for the production of new triazole derivatives

Country Status (22)

Country Link
JP (3) JPS6028825B2 (en)
AT (2) AT345821B (en)
AU (1) AU496929B2 (en)
BE (1) BE830214A (en)
CA (1) CA1074313A (en)
CH (1) CH601264A5 (en)
CS (1) CS189712B2 (en)
DE (1) DE2525691A1 (en)
DK (1) DK227075A (en)
DO (1) DOP1980002934A (en)
ES (4) ES438481A1 (en)
FR (1) FR2274302A1 (en)
GB (1) GB1476116A (en)
GT (1) GT198066871A (en)
HK (1) HK49580A (en)
HU (1) HU172467B (en)
IE (1) IE41550B1 (en)
IL (1) IL47474A (en)
MY (1) MY8100158A (en)
NL (1) NL7507104A (en)
SE (1) SE426393B (en)
ZA (1) ZA753809B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5855147B2 (en) * 1976-06-04 1983-12-08 塩野義製薬株式会社 benzophenone derivatives
CN113372215B (en) * 2021-05-20 2024-05-24 吉林大学 Novel esterification method for synthesizing p-halomethyl benzoate
AR127157A1 (en) 2021-09-29 2023-12-27 Hoffmann La Roche NEW BENZODIAZEPINE DERIVATIVES AS POSITIVE ALLESTERIC MODULATORS OF GABAA g1

Also Published As

Publication number Publication date
ES438481A1 (en) 1977-06-16
AU8208275A (en) 1976-12-16
MY8100158A (en) 1981-12-31
ES454008A1 (en) 1977-11-16
ATA498877A (en) 1978-02-15
JPS6028825B2 (en) 1985-07-06
SE426393B (en) 1983-01-17
SE7505952L (en) 1975-12-15
FR2274302A1 (en) 1976-01-09
JPS59130279A (en) 1984-07-26
GB1476116A (en) 1977-06-10
AU496929B2 (en) 1978-11-09
ES454005A1 (en) 1977-11-16
IL47474A0 (en) 1975-08-31
DOP1980002934A (en) 1986-02-14
BE830214A (en) 1975-12-15
NL7507104A (en) 1975-12-16
JPS617424B2 (en) 1986-03-06
IE41550L (en) 1975-12-14
ES454006A1 (en) 1977-11-16
ZA753809B (en) 1976-05-26
FR2274302B1 (en) 1979-08-17
JPS6021984B2 (en) 1985-05-30
DE2525691A1 (en) 1976-01-02
JPS59108770A (en) 1984-06-23
HK49580A (en) 1980-09-12
CS189712B2 (en) 1979-04-30
AT345822B (en) 1978-10-10
IE41550B1 (en) 1980-01-30
HU172467B (en) 1978-09-28
JPS5111768A (en) 1976-01-30
GT198066871A (en) 1982-06-05
CH601264A5 (en) 1978-06-30
AT345821B (en) 1978-10-10
IL47474A (en) 1980-01-31
DK227075A (en) 1975-12-15
ATA455875A (en) 1978-02-15

Similar Documents

Publication Publication Date Title
AU667107B2 (en) Thiazolylvinylphenyl derivatives
AU769405B2 (en) N-heterocyclic derivatives as NOS inhibitors
EP0178035B1 (en) Anti-inflammatory 1,n-diarylpyrazol-3-amines, compositions containing them and processes for their preparation
US4711890A (en) Pharmaceutical compositions containing azanaphthalene-carboxamide derivatives, azanaphthalene-carboxamide derivatives and process for their use
US4618617A (en) Novel 5-substituted 1,2,4,-oxadiazole derivatives and preparation thereof
FI64157C (en) PROCEDURE FOR FRAMSTATION OF AV 1-ARYL-2- (1-IMIDAZOLYL) ALKYL-ETRAR OCH -TIOETRAR
IL25708A (en) Benzothiophene derivatives and process for their production
US4209515A (en) Triazole derivatives
US4672063A (en) Antiallergic 5-alkyl-1-phenyl-2-piperazinoalkylpyrazolin-3-one compounds
US4377576A (en) 5-(Heterocyclic amino-propionyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-ones
CA1074313A (en) Process for the production of new triazole derivatives
US4670448A (en) Triazole amine compounds, their pharmaceutical compositions and method of use
US5599941A (en) N-substituted trifluoromethylphenyltetrahydropyridines process for the preparation thereof intermediates in said process and pharmaceutical compositions containing them
DE3321012A1 (en) SUBSTITUTED 4,5-DIHYDRO-6- (THIEN-2-YL) -3 (2H) -PYRIDAZINONE AND 6- (THIEN-2-YL) -3 (2H) -PYRIDAZINONE AND METHOD FOR THE PRODUCTION THEREOF
JPS6021994B2 (en) Substituted thienobenzenediazepinone, its acid addition salt, its production process and gastrointestinal drug containing the same
US4612322A (en) Azole type dioxolane derivatives
US4209516A (en) Triazole derivatives
US4388469A (en) Diphenylalkanoether and diphenylalkanone oximeether derivatives
Kawashima et al. Structure-activity studies of 4, 6-disubstituted 2-(morpholinocarbonyl) furo [3, 2-b] indole derivatives with analgesic and antiinflammatory activities
EP0049565A2 (en) Derivatives of substituted N-alkylimidazoles, their preparation and pharmaceutical compositions containing them
US4282223A (en) Isoquinoline derivatives, processes for their manufacture and their use for the manufacture of medicaments
US4588725A (en) 2-piperazinyl-quinazoline derivatives and pharmaceutical compositions containing them
US4459412A (en) 1-Benzylimidazole derivatives
EP1147084B1 (en) Phenylsulphonyl derivatives as 5-ht receptor ligands
US4171366A (en) 1-Naphthothienylalkyl-1H-imidazoles

Legal Events

Date Code Title Description
MKEX Expiry